Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

Method of Providing Protective Immunity against Heterologous Leptospira Strains

The present invention provides compositions and methods for eliciting protective immunity in animals against (LI) serovar The invention is based, in part, on the unexpected cross-protection against heterologous LI serovar, which resulted when canines were administered an effective amount of RECOMBITEK® 4 Lepto, then subsequently challenged with virulent (Fiocruz L1-130). 1Leptospira interroganscopenhagenicopenhageni Leptospira. A method of providing an animal with protective immunity against serovar comprising administering to an animal a vaccine comprising an effective amount of a non-serovar.2. The method of wherein the vaccine is a multivalent/combination vaccine.3Leptospira Interrogansicterohaemorrhagiae.. The method of wherein the vaccine comprises (LI) serovar4icterohaemorrhagiae,canicola,grippotyphosa,pomona.. The method of wherein the vaccine comprises LI LI LI and LI5. The method of wherein the vaccine comprises RECOMBITEK® 4 Lepto claim 3 , as manufactured in the United States in June of 2012.6. The method of wherein the animal is administered about 1 ml of vaccine.7. The method of wherein the animal is administered 2 subcutaneous doses.8. The method of wherein the 2 doses are administered at a 21-day interval.9. The method of any one of the proceeding claims wherein the animal is a canine.10. The method of any one of to wherein the vaccine comprises additional antigens that provide immunity against additional canine pathogens.11. The method of wherein the additional antigens are selected from canine parvovirus (CPV) claim 10 , canine parainfluenza virus (CPi2) claim 10 , canine distemper virus (CDV) claim 10 , adenovirus claim 10 , herpesvirus claim 10 , rabies claim 10 , canine coronavirus claim 10 , and combinations thereof. This application claims priority to provisional application U.S. Ser. No. 61/672,386, filed on Jul. 17, 2012, and incorporated by reference herein in its entirety.The present invention relates generally to immunogenic compositions, ...

Hyperbaric Device and Methods for Producing Inactivated Vaccines and for Refolding/Solubilizing Recombinant Proteins

The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions. 1. A hyperbaric device comprising:(a) an enclosure;(b) at least one computer processor and a programmable user interface therefor;(c) a means for supplying super-ambient pressure;(d) a means for controlling the temperature and pressure of a pressure transmitting fluid;(e) a means for decontaminating the device for routine cleaning purposes or in the event of rupture of a sample pouch; and(f) a means for receiving into the device, conveying within the device, and expelling from the device, trays or receptacles that are adapted to receive sample pouches comprising either microorganisms to be inactivated or peptides to be solubilized and refolded.2. The device of wherein the pressure means comprises an isostatic press comprising a piston.3. The device of further comprising a means to monitor the inactivation status of the microorganisms.4. The device of wherein the inactivation monitoring means comprises a needle or other suitable probe claim 3 , which can aseptically penetrate the pouches to remove a sample of the microorganisms for subsequent viability testing.589. The device of and depicted in claim 1 , wherein pressure is initially communicated to a primary fluid chamber () via a pressure intensifier chamber () claim 1 , which receives ...

Hyperbaric Device and Methods for Producing Inactivated Vaccines and for Refolding/Solubilizing Recombinant Proteins

The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions. 145-. (canceled)46. A hyperbarically-inactivated microorganism that , when administered to an animal in need thereof , elicits a safe and protective immune response in said animal against subsequent challenge with a corresponding live and virulent form of the microorganism; andwherein the inactivated microorganism was inactivated by having subjected the previously living microorganism to defined temperatures and defined pressures for defined periods of time; andwherein the inactivated microorganism is incapable of causing infection or disease in said animal.47Leptospira.. The microorganism of claim 46 , which is of the genus48L. icterohaemorrhagiae, L. canicola, L. pomona, L. grippotyphosaL. bratislava.. The microorganism of claim 47 , which is or49Erysipelothrix.. The microorganism of claim 46 , which is of the genus50Erysipelothrix rhusiopathiae.. The microorganism of claim 49 , which is51Bordetella.. The microorganism of claim 46 , which is of the genus52B. pertussisB. bronchiseptica.. The microorganism of claim 51 , which is or53. A method for producing the hyperbarically-inactivated microorganism of claim 46 , comprising the steps of:(a) subjecting the microorganism to defined elevated pressures for defined periods of time;(b) ...

AUGMENTING THE IMMUNE RESPONSE BY PROMOTING CELL DEATH OF IMMUNE CELLS

Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject. 1. A method , comprisingisolating a dendritic cell sample from a subject and contacting the dendritic cell sample with a caspase inhibitor to produce a modified dendritic cell sample.2. The method of claim 1 , further comprising administering the modified dendritic cell sample to a subject.3. The method of claim 1 , wherein the dendritic cell sample is a purified dendritic cell sample claim 1 , wherein greater than 95% of the cells are dendritic cells.424.-. (canceled)25. A method for vaccinating a subject against an infectious disease agent claim 1 , comprisingadministering to the subject a caspase inhibitor in an effective amount to induce an immune response against the infectious disease agent.26. The method of claim 25 , further comprising administering to the subject an infectious disease antigen.27. The method of claim 25 , wherein the subject has an infection.28. The method of claim 25 , wherein the subject is at risk of exposure to an infectious disease agent.29Borrelia burgdorferi, Escherichia coli, Acinetobacter baumannii, Helicobacter pyloris, Legionella pneumophilia, MycobacteriaM. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonaeStaphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenesStreptococcusStreptococcus agalactiaeStreptococcusStreptococcusStreptococcus faecalis, Streptococcus bovis, StreptococcusStreptococcus pneumoniaeCampylobacterEnterococcusHaemophilus influenzae, Bacillus antracis, Corynebacterium diphtheriae, CorynebacteriumErysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, BacteroidesFusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema pertenue, Leptospira, RickettsiaActinomyces ...

COMPOSITIONS AND METHODS OF PREPARING LEPTOSPIRA

The present invention includes compositions and methods of preparing flagellar-coiling protein 1 (Fcp1)-deficient bacterium. In one aspect, the invention includes an isolated, flagellar-coiling protein 1 (Fcp1)-deficient bacterium. Another aspect includes a composition comprising a flagellar-coiling protein 1 (Fcp1) deficient bacterium. Yet another aspect includes a method of producing a motility-deficient bacterium comprising inhibiting expression of a wild-type flagellar-coiling protein 1 (Fcp1) gene. Methods of stimulating an immune response and reducing or treating an infectious disease caused by one or more bacteria in a subject in need thereof comprising administering a composition comprising an effective amount of flagellar-coiling protein 1 (Fcp1) deficient bacteria to the subject are also included. 1Leptospira. An isolated , flagellar-coiling protein 1 (Fcp1)-deficient bacterium.2LeptospiraLeptospira. The bacterium of claim 1 , wherein the bacterium comprises a silenced or deleted Fcp1 gene.3LeptospiraLeptospira. The bacterium of claim 1 , wherein the bacterium comprises a mutant Fcp1 gene.4Leptospira. The bacterium of claim 1 , wherein the mutant Fcp1 gene expresses a mutant protein incapable of functioning as wildtype Fcp1.5LeptospiraLeptospira. The bacterium of claim 1 , wherein the bacterium is motility-deficient.6LeptospiraLeptospira. The bacterium of claim 1 , wherein the bacterium has attenuated bacterial virulence.7LeptospiraLeptospira. The bacterium of claim 1 , wherein the bacterium is non-pathogenic.8Leptospira. A composition comprising a flagellar-coiling protein 1 (Fcp1) deficient bacterium.9Leptospira. The composition of claim 8 , wherein the bacterium comprises a silenced or deleted Fcp1 gene.10Leptospira. The composition of claim 8 , wherein the bacterium comprises a mutant Fcp1 gene.11. The composition of claim 10 , wherein the mutant Fcp1 gene expresses a mutant protein incapable of functioning as wildtype Fcp1 protein.12Leptospira. The ...

VACCINE STRAINS OF BRACHYSPIRA HYODYSENTERIAE

The present invention relates to strains and their use in diagnosis or treatment. In addition, the invention provides a vaccine against diarrheal disease, in particular swine dysentery. 1Brachyspira hyodysenteriaeB. hyodysenteriae. An isolated strain of () comprising the genes encoding the polypeptides comprising the following amino acid sequences: SEQ ID NO:10 , SEQ ID NO:11 , SEQ ID NO: 12 , SEQ ID NO: 13 , SEQ ID NO: 14 and SEQ ID NO: 15 , or a sequence having at least 95% identity thereto.2. The strain according to claim 1 , wherein the genes comprise the following nucleic acid sequences: SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO: 4 claim 1 , SEQ ID NO: 5 and SEQ ID NO: 6 claim 1 , or a sequence having at least 95% identity thereto.3. The strain according to claim 1 , wherein the strain further comprises the plasmid encoded virulence associated genes BHWA1_02678 claim 1 , BHWA1_02679 claim 1 , BHWA1_02680 and BHWA1_02681.4. The strain according claim 1 , wherein the strain is the strain deposited on 23 Oct. 2015 at the Belgian Co-ordinated Collections of Micro-Organisms under BCCM Deposit No. LMG P-29184.5B. hyodysenteriae. A composition comprising at least one strain of according to claim 1 , and a pharmaceutically acceptable carrier claim 1 , excipient and/or diluent.611.-. (canceled)12B. hyodysenteriae. A kit for vaccination of an animal against infection comprising: (a) a composition comprising at least one vaccine strain according to ; and (b) instructions for vaccinating the animal.13B. hyodysenteriae,B. hyodysenteriae;B. hyodysenteriae.. An in vitro method of identifying a candidate vaccine strain of the method comprising: (a) obtaining a sample of and (b) determining the presence or absence of the nucleic acid molecules as depicted in SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO: 4 claim 1 , SEQ ID NO:5 and SEQ ID NO: 6 claim 1 , and/or the expression of corresponding mRNA or protein ...

Leptospira Immunoprotective Proteins and Methods of Identification and Use Thereof

The present invention provides compositions and methods for eliciting heterologous protective immunity in animals against Leptospira spp. The Leptospira spp. immunoprotective peptides disclosed herein elicit protective immunity against subsequent challenge or exposure to at least two Leptospira spp. serovars.

IMMUNOGENIC COMPOSITION OF KILLED LEPTOSPIRA BACTERIA

The present invention pertains to a composition containing an immunogenic cell preparation of killed bacteria in an ethylenediaminetetraacetic acid solution. The invention also pertains to a vaccine to protect an animal against an infection with bacteria, wherein the vaccine comprises this composition. Also, the invention pertains to the use of ethylenediaminetetraacetic acid to stabilise an immunogenic preparation of killed bacteria in a liquid carrier, by dissolving the ethylenediaminetetraacetic acid in the carrier. 111-. (canceled)12Leptospira. A composition containing an immunogenic cell preparation of killed bacteria in an ethylenediaminetetraacetic acid solution.13. The composition of claim 12 , wherein the solution comprises 5 to 50 mmols of ethylenediaminetetraacetic acid per litre.14. The composition of claim 13 , wherein the solution comprises 20 mmols of ethylenediaminetetraacetic acid per litre.15. The composition of claim 14 , wherein the solution contains dibasic sodium phosphate.16. The composition of claim 13 , wherein the solution contains dibasic sodium phosphate.17. The composition of claim 12 , wherein the solution contains dibasic sodium phosphate.18LeptospiraLeptospira interrogansLeptospira interrogansLeptospira kirschneri. The composition of claim 17 , wherein the bacteria are selected from the group consisting of serogroup Canicola serovar Portland-Vere claim 17 , serogroup Icterohaemorrhagiae serovar Copenhageni and serogroup Grippotyphosa serovar Dadas.19LeptospiraLeptospira interrogansLeptospira interrogansLeptospira. The composition of claim 12 , wherein the bacteria are selected from the group consisting of serogroup Canicola serovar Portland-Vere claim 12 , serogroup Icterohaemorrhagiae serovar Copenhageni and kirschneri serogroup Grippotyphosa serovar Dadas.20LeptospiraLeptospira. The composition of claim 19 , wherein the bacteria are interrogans serogroup Canicola serovar Portland-Ver.21. A vaccine to protect an animal against an ...

BOVINE VACCINES AND METHODS

Methods for stimulating immune responses in a bovine animal susceptible to infection by -are disclosed. In the methods, a composition of inactivated -and an adjuvant is administered to the animal within about 4 weeks of birth. The immune responses stimulated in the animal prevent or shorten the duration of a subsequent -infection. The immune response is effective for at least a year. 1Leptospira: A method for stimulating an immune response effective against in bovine animals , comprising:{'i': Leptospira borgpetersenii', 'hardjo', 'hardjo', 'bovis', 'L. hardjo', 'bovis, 'administering to the animals, at between about 4 to 26 weeks of age, a composition that includes an immunogenic amount of inactivated , serovar , type -, (-) and an adjuvant,'}{'i': L. hardjo', 'bovis, 'wherein the administering stimulates an immune response specific for -in the animals, which aids in prevention of chronic leptospirosis.'}2L. hardjobovis.: The method of claim 1 , wherein the administering to animals between 4 to 26 weeks of age is followed claim 1 , within about 8 weeks later claim 1 , by a second administering of an immunogenic amount of inactivated -3L. hardjo bovisL. hardjo bovis: The method of claim 1 , wherein aids in prevention of chronic leptospirosis means that detection of in animals administered the composition is decreased claim 1 , for up to about 1 year subsequent to the administering claim 1 , as compared to detection of in similar animals not administered the composition.4Leptospira interroganscanicola, grippotyphosa, icterohaemorrhagiaepomonaCampylobacter fetusHistophilus somni: The method of claim 1 , wherein the composition includes additional components claim 1 , including one or more of inactivated claim 1 , serovars and claim 1 , inactivated claim 1 , inactivated claim 1 , inactivated bovine virus diarrhea type 1 claim 1 , inactivated bovine virus diarrhea type 2 claim 1 , inactivated parainfluenza type 3 claim 1 , inactivated bovine respiratory syncytial virus ...

Immunostimulatory preparation exhibiting antitumor activity

The proposed preparation and methods relate to medicinal microbiology and pharmacology, and relate to preparations exhibiting an immunostimulatory effect, which may be used for the prevention and treatment of oncological diseases. The essence of the preparation and methods consists in a primary component of the preparation including a polyvalent corpuscular antigen, prepared on the basis of culture strains. The proposed preparation exhibits an immunostimulatory effect, with a primary influence on components of T-cell immunity. The proposed preparation, in a preventative therapeutic application, is effective with regard to tumors of various histogenesis. 1Treponema pallidum. A preparation for the prevention and treatment of oncological diseases , characterized in that it contains the causative agent of syphilis as the main component.2Treponema pallidum. The preparation according to claim 1 , wherein it comprises native or inactivated corpuscular antigens prepared from culture strains as the main component.3. The preparation according to claim 1 , wherein it comprises a mixture of inactivated corpuscular antigens of at least three laboratory treponemes strains as the main component.4. The preparation according to claim 3 , wherein the strains refer to at least three antigenic groups of the pathogen.5. The preparation according to claim 2 , wherein inactivated corpuscular antigens of treponemes strains sorbed on aluminum hydroxide are used.6Treponema pallidum. The preparation according to for the treatment of oncological diseases claim 2 , wherein it comprises a mixture of heat-inactivated and phenol-preserved microbes of culture strains.7Treponema pallidum. The preparation according to for the prevention of oncological diseases claim 2 , wherein it contains a mixture of heat-inactivated claim 2 , adsorbed on aluminum hydroxide and phenol-preserved microbes of culture strains.8. A method for producing the preparation according to claim 1 , comprising: preparing seed ...

STRINGS OF EPITOPES USEFUL IN DIAGNOSING AND ELICITING IMMUNE RESPONSES TO SEXUALLY TRANSMITTED INFECTIONS

The invention provides methods and compositions for detecting and diagnosing sexually transmitted infections using a string of epitopes (SOE) specific for detection of causative microorganisms. The antigenic epitopes may be single epitope sequences a plurality of epitope sequences joined by repeats of glycine (-GG-) and/or lysine (-KK-) to form a series of epitopes (SOE), or nucleotide sequences encoding one or more SOEs and host cells harboring said SOE nucleotide sequences. SOEs specific for highly immunogenic regions of proteins from and species are provided. SOEs to detect the presence of species comprise regions from -sptciric aldolase, GAPDH, α-enolase and α-actinin proteins. Pharmaceutical compositions comprising SOEs can also be used as vaccines or to elicit an immune response to specific microorganisms. 1. A method for detecting the presence of one or more microorganisms in a biological sample of a subject , comprising the steps of:combining said biological sample with a polypeptide including a series of epitopes (SOE) which includes a plurality of 4-mer to 30-mer amino acid sequences, each of said 4-mer to 30-mer amino acid sequences encode an immunogenic region of at least one protein expressed by said one or microorganisms, said plurality of 4-mer to 30-mer amino acid sequences being arranged as a linear array with each of said plurality of 4-mer to 30-mer amino acid sequences being connected by one or more repeats of amino acid linkers selected from the group consisting of glycine-glycine (-GG-) and lysine (-KK-), wherein said combining is performed under conditions whereby antigen-antibody complexes are permitted to form; anddetecting formation of at least one antigen-antibody complex as an indication of a presence of at lease one microorganism of said one or more microorganisms in said biological sample.2. The method of claim 1 , wherein said SOE includes at least six 4-mer to 30-mer amino acid sequences.3. The method of claim 1 , wherein said SOE ...

POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN

A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian infections. 1. A chimeric protein comprising epitopes from loop 5 region or alpha helix 5 region , or both , of two or more outer surface protein C (OspC) types.2. The chimeric protein of that comprises an epitope from a loop 5 region of OspC types F claim 1 , M claim 1 , D claim 1 , I claim 1 , H claim 1 , or C.3. The chimeric protein of claim 2 , wherein said epitope from said OspC type M loop 5 region comprises SEQ ID NO: 19 claim 2 , said epitope from said OspC type D loop 5 region comprises SEQ ID NO: 7 claim 2 , said epitope from said OspC type I loop 5 region comprises SEQ ID NO: 12 claim 2 , said epitope from said OspC type H loop 5 region comprises SEQ ID NO: 11 claim 2 , said epitope from said OspC type N loop 5 region comprises SEQ ID NO: 20 claim 2 , and said epitope from said OspC type C loop 5 region comprises SEQ ID NO: 6.4. The chimeric protein of that comprises said epitopes from at least two of said loop 5 regions from different OspC types.5. The chimeric protein of wherein said epitopes from at least two of said loop 5 regions are from at least two different OspC types from Osp C type F claim 4 , M claim 4 , D claim 4 , I claim 4 , H claim 4 , N or C.6. The chimeric protein of wherein said epitope from said OspC type M loop 5 region comprises SEQ ID NO: 19 claim 5 , said epitope from said OspC type D loop 5 region comprises SEQ ID NO: 7 claim 5 , said epitope from said OspC type I loop 5 region comprises SEQ ID NO: 12 claim 5 , said epitope from said OspC type H loop 5 region comprises SEQ ID NO: 11 claim 5 , said epitope from said OspC type N loop 5 region comprises SEQ ID NO: 20 claim 5 , and said epitope from said OspC type C loop 5 region comprises SEQ ID NO: ...

Oral Vaccine For Borrelia

The present invention relates to vaccines for control of infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried. 1Borrelia burgdorferi.. A composition comprising a bacterium engineered to express at least one outer surface protein of2E. coli.. The composition of claim 1 , wherein said bacterium comprises lyophilized3L. acidophilus, L. brevis, L. casei, L. crispatus, L. fermentum, L. gasseri, L. plantarum, L. reuteri, L. rhamnosus,L. salivarius.. The composition of claim 1 , wherein said bacterium comprises a lactobacillus selected from the group consisting of and4L. plantarum.. The composition of claim 1 , wherein said lactobacillus comprises5. The composition of claim 1 , wherein said at least one outer surface protein comprises an OspA fragment of at least 100 amino acids that is at least 90% identical to the amino acid sequence set forth as SEQ ID NO:2.6. The composition of claim 1 , wherein said at least one outer surface protein comprises an OspA fragment of at least 200 amino acids that is at least 80% identical to the amino acid sequence set forth as SEQ ID NO:2.7. The composition of claim 1 , wherein said at least one outer surface protein comprises an OspA fragment with a mutated hLFA1 epitope.8. The composition of claim 1 , wherein said at least one outer surface protein comprises an OspC fragment of at least 100 amino acids that is at least 80% identical to the amino acid sequence set forth as SEQ ID NO :4.9. The composition of claim 1 , wherein said at least one outer surface protein comprises an OspC fragment of at least 150 amino acids that is at least 85% identical to the amino acid sequence set forth as SEQ ID NO:4.10. The composition of claim 1 , wherein said at least one outer surface protein comprises one or both of an ...

Panel comprising Borrelia MHC multimers

Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of -specific T cells and the diagnosis, treatment and monitoring of disease in an individual.

NOVEL GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF

Novel polynucleotide and amino acids of are described. These sequences are useful for diagnosis of disease in animals and as a therapeutic treatment or prophylactic treatment of disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other species, including , and 1. An isolated polypeptide comprising the full length of an amino acid sequence selected from the group consisting of SEQ ID NO: 22 , 32 , and 64 with a heterologous polypeptide that permits the detection , isolation , solubilization , or stabilization of the isolated polypeptide.25-. (canceled)6. An immunogenic composition comprising the polypeptide of .730-. (canceled)31Brachyspira. A method of generating an immune response to infection in an animal comprising administering to said animal the polypeptide of .3244-. (canceled)45. An isolated polypeptide comprising a sequence that is at least 70% homologous to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 22 claim 1 , 32 claim 1 , and 64 and a heterologous polypeptide that permits the detection claim 1 , isolation claim 1 , solubilization claim 1 , or stabilization of the isolated polypeptide.46. An isolated polypeptide comprising a sequence that is at least 80% homologous to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 22 claim 1 , 32 claim 1 , and 64 and a heterologous polypeptide that permits the detection claim 1 , isolation claim 1 , solubilization claim 1 , or stabilization of the isolated polypeptide.47. An isolated polypeptide comprising a sequence that is at least 90% homologous to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 22 claim 1 , 32 claim 1 , and 64 and a heterologous polypeptide that permits the detection claim 1 , isolation claim 1 , solubilization claim 1 , or stabilization of the isolated polypeptide.48. An ...

Mutant fragments of ospa and methods and uses relating thereto

The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.

Compositions And Methods For Immunodominant Antigens

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (, human Herpes virus 1 and 2, , and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter. 1. An isolated antigen composition comprising:a plurality of immunodominant antigens of a pathogenic organism associated with a carrier;wherein the antigens have quantified and known relative reactivities with respect to sera of a population infected with the organism;wherein the antigens are determined to have a known association with a disease parameter; and{'sub': —', '—, 'wherein the plurality of antigens are encoded by nucleic acids selected from the group consisting of SEQ ID NO:633 (BB_A19), SEQ ID NO:575 (BB_A25), SEQ ID NO:595 (BB_K07), SEQ ID NO:596 (BB_K12), SEQ ID NO:14 (BB0147), SEQ ID NO:550 (BB0279), and SEQ ID NO: 637 (VIsE), or fragments thereof.'}2Borrelia burgdorferi. The antigen composition of further comprising at least one additional antigen of claim 1 , encoded by nucleic acids selected from the group consisting of SEQ ID NO:546 to SEQ ID NO:637.3. The antigen composition of wherein the carrier is a pharmaceutically acceptable carrier claim 1 , and wherein the composition is formulated as a vaccine.4. The antigen composition of wherein the vaccine comprises at least four antigens.5. The antigen composition of wherein the vaccine comprises antigens from at least two distinct pathogens.6. The antigen composition of wherein the antigens or fragments thereof are recombinant.7. The antigen composition of wherein the antigens or fragments thereof are at least partially purified.8. The antigen composition of wherein the carrier is a solid carrier claim 1 , and wherein the plurality of antigens is ...

CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis. 127-. (canceled)28. A nucleic acid molecule selected from the group consisting of:(a) a nucleic acid molecule comprising a nucleotide sequence with at least about 79 percent sequence identity with the nucleic acid sequence set forth in SEQ ID NO: 172;(b) a nucleic acid molecule comprising a nucleotide sequence comprising the nucleotide sequence set forth in SEQ ID NO: 172;(c) a nucleic acid molecule comprising a nucleotide sequence consisting of the nucleotide sequence set forth in SEQ ID NO: 172;(d) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide with at least about 79 percent sequence identity with the amino acid sequence set forth in SEQ ID NO: 173; and(e) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 173, the polypeptide having a substitution of one to 25 conservative amino acids;(f) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 173, the polypeptide having an insertion of one to 25 conservative amino acids;(g) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 173, the polypeptide having an internal deletion of one to 25 conservative amino acids;(h) a nucleic ...

DbpA ANTIBODIES AND USES THEREOF

Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia. Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.

METHOD FOR REDUCING ZOONOTIC INFECTIOUS DISEASES

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition. 1Escherichia coli. A method of controlling zoonotic infectious diseases by vaccinating a subject in need thereof comprising orally administering to the subject a composition for oral delivery of a bait foodstuff , said bait foodstuff comprising: i) a bait substrate having a surface; ii) an effective amount of at least one antigenic agent layered over said substrate , wherein said at least one antigenic agent is stabilized within a stabilizer under conditions facilitating anhydrobiosis , said stabilizer selected from at least one of the group consisting of a hydrocolloid polymer and a plasticizing sugar , complexed in solution with a phosphate-buffered saline liquid carrier; and iii) a calcium salt cross-linking agent to facilitate encapsulation of said antigenic agent within said stabilizer on said surface of said substrate; wherein said antigenic agent is a bacterial vehicle , said bacterial vehicle defined by a recombinant whole-cell OspA-vectored bacteria engineered to express at least one antigen.2. The method of wherein said calcium salt cross-linking agent is selected from the group consisting of calcium lactate claim 1 , calcium chloride claim 1 , calcium sulfate claim 1 , calcium carbonate claim 1 , calcium acetate claim 1 , calcium ascorbate claim 1 , and any combination thereof.3. The method of wherein said stabilizer is both a hydrocolloid polymer and a plasticizing sugar.4. The method of wherein said hydrocolloid polymer is a sodium alginate. ...

Vaccines and methods to treat lyme disease in dogs

The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi . Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.

Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of Lyme disease vaccine

The present invention relates to a Lyme disease vaccine, a genetic construct, recombinant protein, method for genetic construct design, method for vaccine delivery, method for recombinant proteins delivery, use of recombinant proteins in the production of Lyme disease vaccine. In particular, the method concerns the use of TROSPA and TROSPA-Salp15 recombinant proteins derived from castor bean tick () as a component of Lyme disease vaccine for animals. The antibodies present in blood of an immunized vertebrate directed against the TROSPA proteins considerably reduce the chance of infecting new ticks by blocking or hindering the interaction of TROSPA protein with OspA protein of sensu lato. The interaction is crucial in the process of the spirochete entering a tick. The antibodies directed against the TROSPA-Salp15 protein protect vertebrates from infection on the stage of diffusion by destroying their protective coating formed at the surface as a result of the interaction between the Salp15 tick protein and OspC spirochete protein. The vaccine based on TROSPA tick proteins and TROSPA-Salp15 proteins may be used independently or together with the OspA recombinant proteins and OspC protein of sensu lato. 1. A TROSPA genetic construct comprising TROSPA genetic sequence as defined by SEQ. ID NO: 1.2. A TROSPA-Salp 15 genetic construct comprising TROSPA-Salp 15 genetic sequence as defined by SEQ. ID NO: 2.3. A recombinant TROSPA protein defined by SEQ. ID NO: 3 and encoded by said TROSPA genetic construct and has immunogenic properties.4. A recombinant TROSPA-Salp 15 protein , defined by SEQ. ID NO: 4 and encoded by said TROSPA-Salp 15 genetic construct and has immunogenic properties.5of Borrelia burgdorferi. The recombinant protein of or wherein said recombinant protein interacts with the OspA protein sensu lato to make an antigen.6. A vaccine comprising said antigen from said recombinant TROSPA protein of defined by SEQ. ID. No: 3 or said recombinant TROSPA-Salp15 ...

BORRELIA IMMUNOASSAYS AND MATERIALS THEREFOR

The present invention relates to an immunoassay for the detection of specific IgG, IgM and IgG/IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen/substrate combinations and compositions comprising combinations of the disclosed peptides and/or proteins for use in the immunoassays described herein.

LEPTOSPIRA WITH INCREASED ANTIGENIC MASS

The antigenic mass of cultures can be significantly increased, independent from any increase in biomass, by supplementing cultures with a specific fatty acid: linoleic acid. This provides advantages in the production antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective. 1LeptospiraLeptospira. A method for increasing the antigenic mass of a culture , the method comprising the step of supplementing said culture with linoleic acid.2Leptospira. The method according to claim 1 , the method comprising the step of incubating a culture under conditions in which at least 15 μg linoleic acid/ml was made available to said culture.3LeptospiraLeptospira. The culture obtainable by a method according to claim 1 , wherein said culture has an increased antigenic mass.4Leptospira. The culture according to claim 3 , or a preparation of said culture claim 3 , for use in a vaccine against Leptospirosis.5Leptospira. A vaccine against Leptospirosis comprising a culture according to claim 3 , or a preparation of said culture.6. A method for producing a vaccine against Leptospirosis claim 3 , said method comprising the steps of:{'i': 'Leptospira', 'a. proliferating a culture in an in vitro system,'}{'i': 'Leptospira', 'b. supplementing said culture with linoleic acid,'}{'i': 'Leptospira', 'c. inactivating and harvesting said supplemented culture, and'}{'i': 'Leptospira', 'd. admixing the inactivated culture with a pharmaceutically acceptable carrier.'}7Leptospira. The method according to claim 6 , wherein between steps a. and b. there is an additional step comprising harvesting claim 6 , storage and/or purification claim 6 , of the culture. The current invention generally relates to the fields of bacteriology, and to bacterial vaccines. In particular the invention relates to a method for increasing the antigenic mass of , to the obtainable by that method, and to vaccines and uses of suchThe spirochete bacteria of the genus belong ...

MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a infection and a method of immunizing a subject. 148.-. (canceled)49Borrelia. A polypeptide comprising a mutant fragment of outer surface protein A (OspA) , wherein said mutant OspA fragment is defined by SEQ ID NO: 218 , or a functional variant thereof.50. The polypeptide according to claim 49 , wherein said functional variant has at least 95% sequence identity to the wild-type OspA fragment.51. The polypeptide according to claim 49 , wherein said polypeptide comprises a heterodimer selected from the group consisting of Lip-S5D1-S6D1 (SEQ ID NO: 190) claim 49 , Lip-S6D1-S5D1 (SEQ ID NO: 196) claim 49 , S5D1-S6D4 (SEQ ID NO: 202) and S6D4-S5D1 (SEQ ID NO: 207).52. The polypeptide according to claim 49 , wherein said polypeptide consists of a heterodimer selected from the group consisting of Lip-S5D1-S6D1 (SEQ ID NO: 190) claim 49 , Lip-S6D1-S5D1 (SEQ ID NO: 196) claim 49 , S5D1-S6D4 (SEQ ID NO: 202) and S6D4-S5D1 (SEQ ID NO: 207).53. A nucleic acid molecule encoding the polypeptide according to .54. A pharmaceutical composition comprising the polypeptide according to and optionally a pharmaceutically acceptable carrier or excipient.55. The pharmaceutical composition according to claim 54 , wherein said excipient is L-methionine and/or aluminium hydroxide.56. A pharmaceutical composition comprising the nucleic acid molecule according to and optionally a pharmaceutically acceptable carrier or excipient.57. A pharmaceutical composition comprising Lip-S5D1-S6D1 (SEQ ID NO: 190) and/or Lip-S1D1-S2D1 (SEQ ID NO: 186) and claim 53 , optionally claim 53 , a pharmaceutically acceptable carrier or excipient.58. The ...

MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a infection and a method of immunizing a subject. 119.-. (canceled)20. A method for producing a polypeptide comprising a mutant fragment of an outer surface protein A (OspA) , wherein the mutant OspA fragment is defined by SEQ ID NO: 216 , or a functional variant thereof , the method comprising the following steps:a) introducing a vector encoding the polypeptide into a host cell,b) growing the host cell under conditions allowing for expression of said polypeptide,c) homogenizing said host cell, andd) subjecting the host cell homogenate to purification steps.21. The method according to claim 20 , wherein said functional variant has at least 95% sequence identity to the wild-type OspA fragment.22. The method according to claim 20 , wherein the polypeptide comprises a heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO: 186) claim 20 , Lip-S2D1-S1D1 (SEQ ID NO: 192) claim 20 , Lip-S1D1-S2D4 (SEQ ID NO: 198) and Lip-S2D4-S1D1 (SEQ ID NO: 203).23. The method according to claim 20 , wherein the polypeptide consists of a heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO: 186) claim 20 , Lip-S2D1-S1D1 (SEQ ID NO: 192) claim 20 , Lip-S1D1-S2D4 (SEQ ID NO: 198) and Lip-S2D4-S1D1 (SEQ ID NO: 203).24. The method according to claim 20 , wherein the vector comprises a nucleic acid molecule encoding said polypeptide.25. The method according to claim 24 , wherein said nucleic acid molecule encoding said polypeptide is defined by SEQ ID NO: 48.26. The method according to claim 20 , wherein said vector is pET28b(+).27E. coli.. The method according to claim 20 , wherein said host cell is28E ...

VACCINE CANDIDATE FOR PERIODONTITIS

A complementary DNA (cDNA) with SEQ ID NO: 1 which encodes an immunogenic fragment of major outer sheath protein (Msp) of 1Treponema denticola.. A complementary DNA (cDNA) , wherein the cDNA comprises SEQ ID NO: 1 and encodes an immunogenic fragment of major outer sheath protein (Msp) of2. The cDNA of claim 1 , wherein the cDNA encodes the immunogenic fragment with a molecular weight of 9722 Daltons.3. The cDNA of claim 1 , wherein the cDNA encodes the immunogenic fragment with an isoelectric point of 9.19.4. The cDNA of claim 1 , wherein the cDNA further comprises a nucleotide sequence of a histidine tag (His-tag).5. A method for vaccination against periodontitis claim 1 , the method comprising:administering a DNA vaccine to a subject, the DNA vaccine comprising a complementary DNA (cDNA) with SEQ ID NO: 1.6. The method of claim 5 , wherein the DNA vaccine further comprises an adjuvant.7. The method of claim 6 , wherein the adjuvant comprises Freund's adjuvant.8. The method of claim 5 , wherein the DNA vaccine further comprises a pharmaceutically acceptable carrier.9. A method for vaccination against periodontitis claim 5 , the method comprising: [{'i': 'Treponema denticola', 'an immunogenic fragment of major outer sheath protein (Msp) of comprising SEQ ID NO: 2 with a concentration between 50 μg/ml and 200 μg/ml; and'}, "Freund's adjuvant."], 'administering a peptide vaccine to a subject, the peptide vaccine comprising10. The method of claim 9 , wherein the peptide vaccine further comprises a pharmaceutically acceptable carrier.11. The method of claim 9 , wherein the peptide vaccine comprises the immunogenic fragment and the Freund's adjuvant with a volume ratio of 1:1. This application claims the benefit of priority from pending U.S. Provisional Patent Application Ser. No. 62/787,396, filed on Jan. 2, 2019, and entitled “PERIOVAX3, A VACCINE CANDIDATE FOR PERIODONTITIS,” which is incorporated herein by reference in its entirety.The present disclosure generally ...

IMMUNGENIC TP0751 FRAGMENTS

The present application provides methods of stimulating an immune response, such as a protective immune response against infection. Such methods utilize fragments of the Tp0751 protein (such as any of SEQ ID NOs: 3-10, those N-terminally truncated from amino acids 1 through 77, 1 through 114, or anywhere in between, e.g., those that start at any amino acid from 78 to 115). In some examples, a Tp0751 protein fragment has a mutated HEXXH site (HEXXH is the wild-type sequence). Also provided are the isolated soluble Tp0751 protein fragments that include a wild-type or mutated HEXXH site, as well as nucleic acids encoding such proteins and kits that include such proteins. 1. A method of stimulating an immune response against a Tp0751 protein , comprising:administering a therapeutically effective amount of a Tp0751 protein fragment to a subject, wherein the Tp0751 protein fragment comprises at least 123 consecutive amino acids of the C-terminus of SEQ ID NO: 2.2Treponema pallidum.. The method of claim 1 , wherein the method induces serum antibodies which have neutralizing activity for3Treponema pallidum. The method of claim 1 , wherein the method is a method for vaccinating a human against infection.4Treponema pallidum.. The method of claim 2 , wherein the antibodies protect the human against infection by5. The method of claim 1 , wherein the Tp0751 protein fragment comprises an amino acid sequence:(a) shown in SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 15, 16, 18, 19, or 21;(b) having at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% sequence identity to an amino acid sequence shown in SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 15, 16, 18, 19, or 21;(c) shown in SEQ ID NO: 15 and further comprising a mutation at amino acid 121, 122, and/or 125;(d) shown in SEQ ID NO: 16 and further comprising a mutation at amino acid 121, and/or 125;(e) shown in SEQ ID NO: 18 and further comprising a mutation at amino acid 100, 101, and/or 104;(f) shown in SEQ ID ...

COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI

Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against , including administering to the subject an effective amount of the immunogenic composition 120-. (canceled)21. New. An immunogenic composition , comprisinga peptide, wherein consecutive amino acids of the peptide comprise consecutive amino acids of SEQ ID NO:1 and the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-193 of SEQ ID NO:1, 187-194 of SEQ ID NO:1, 188-195 of SEQ ID NO:1, 189-196 of SEQ ID NO:1, and any combination of two or more of the foregoing, wherein one or both of amino acids 189 and 193 of SEQ ID NO:1 comprises alanine or is independently substituted with any other amino acid except tyrosine, andone or more adjuvant, wherein at least one of the one or more adjuvant is selected from an aluminum salt, AS04, AS03, monophosphoryl lipid A, poly(I:C), a CpG DNA adjuvant, MF59, an emulsion adjuvant comprising squalene and water, a combination adjuvant comprising block copolymer CRL-8300, squalene, a sorbitan monooleateor, N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium salt (DOTAP), 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-chol liposome), and a virosomal adjuvant.22. The immunogenic composition of claim 21 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 1-193 of SEQ ID NO:1 claim 21 , 1-194 of SEQ ID NO:1 claim 21 , 1-195 of SEQ ID NO:1 claim 21 , 1-196 of SEQ ID NO:1 claim 21 , and any combination of two or more of the foregoing claim 21 , wherein one or both of amino acids 189 and 193 of SEQ ID NO:1 comprises alanine or is independently substituted with any other amino acid except ...

VACCINATION RESPONSE FOR IMMUNODEFICIENCY DISORDERS OR HIGH CORTISOL

A method of improving a human's response to vaccination with a vaccine enhancement food. This food contains at least transfer factor and lactic acid generating bacteria, and in some embodiments includes glucans. The vaccine enhancement food may be consumed before, during, or after the vaccination. The results are an improvement in the vaccine titer, a slower decay of titer, longer periods of immunity, and fewer needed boosters. 1. A method of increasing the antibody production of a vaccine for a mammal , comprising:administering a transfer factor formulation comprising at least transfer factor to the mammal before, during, or after the vaccine is administered, wherein each dosage is present at 0.05 to 50 mg per pound of the mammal's body weight and the formulation is into a solution for injection, into a food for consumption, or into a liquid for consumption, and wherein more antibodies are created by the vaccine plus formulation than are created by the vaccine without the formulation.2. The method of wherein the transfer factor formulation further comprises lactic acid generating bacteria.3. The method of wherein the lactic acid generating bacteria in each dosage is present at 0.47-10 mg per pound of the mammal's body weight.4. The method of further comprising measuring a vaccine antibody titer to quantify the increasing.5. The method of wherein the antibody titer is specific to any one disease selected from the group consisting of bordetella pertussis claim 4 , haemophilus influenzae b. neisseria meningitides claim 4 , poliovirus claim 4 , streptococcus pneumoniae claim 4 , tetanus toxoid claim 4 , diphtheria toxoid claim 4 , rabies virus claim 4 , polio claim 4 , measles claim 4 , mumps claim 4 , rubella claim 4 , and human papillomavirus.6. The method of wherein the transfer factor formulation further comprises one or more additives selected from the group consisting of glucans claim 1 , hetero-polysaccharides claim 1 , vitamins claim 1 , electrolytes claim 1 , ...

AUGMENTING THE IMMUNE RESPONSE BY PROMOTING CELL DEATH OF IMMUNE CELLS

Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject. 1. A method , comprisingisolating a dendritic cell sample from a subject and contacting the dendritic cell sample with a caspase inhibitor to produce a modified dendritic cell sample.2. The method of claim 1 , further comprising administering the modified dendritic cell sample to a subject.3. The method of claim 1 , wherein the dendritic cell sample is a purified dendritic cell sample claim 1 , wherein greater than 95% of the cells are dendritic cells.424-. (canceled)25. A method for vaccinating a subject against an infectious disease agent claim 1 , comprisingadministering to the subject a caspase inhibitor in an effective amount to induce an immune response against the infectious disease agent.26. The method of claim 25 , further comprising administering to the subject an infectious disease antigen.27. The method of claim 25 , wherein the subject has an infection.28. The method of claim 25 , wherein the subject is at risk of exposure to an infectious disease agent.29Borrelia burgdorferi, Escherichia coli, Acinetobacter baumannii, Helicobacter pyloris, Legionella pneumophilia, MycobacteriaM. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonaeStaphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenesStreptococcusStreptococcus agalactiaeStreptococcusStreptococcusStreptococcus faecalis, Streptococcus bovis, StreptococcusStreptococcus pneumoniae, pathogenic CampylobacterEnterococcusHaemophilus influenzae, Bacillus antracis, corynebacterium diphtheriae, corynebacteriumErysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, BacteroidesFusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema pertenue, Leptospira, ...

METHODS OF VACCINE ADMINISTRATION

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein. 1Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona, L. bratislavaBordetella bronchiseptica. A method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of vaccine , wherein the vaccine comprises viral antigens , a bacterin , or both , and wherein the vaccine is administered subcutaneously or orally in a first dose , orally in a second dose , orally in an optional third dose , and orally in one or more annual doses , and wherein the viral antigens comprise one or more of 1) canine distemper (CD) virus , 2) canine adenovirus type 2 (CAV-2) , 3) canine parainfluenza (CPI) virus , 4) canine parvovirus (CPV) , 5) and canine coronavirus (CCV) , and wherein the bacterin comprises one or more bacteria selected from , and ; and any combination of viral antigens and bacteria thereof.2Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona, L. bratislavaBordetella bronchiseptica. A method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of vaccine , wherein the vaccine comprises viral antigens , a bacterin , or both , and wherein the vaccine is administered subcutaneously in a first and in a second dose , and orally in a third dose , and orally in one or more annual doses , and wherein the viral antigens comprise one or more of 1) CD virus , 2) CAV-2 , 3) CPI virus , 4) CPV , 5) and CCV , and the bacterin comprises one or more bacteria selected from , and ; and any combination of viral antigens and bacteria thereof.3. A method according to or , wherein the viral antigens are CD virus , CAV-2 , CPI ...

SWINE DYSENTERY VACCINE

The present invention relates to a composition comprising bacteria, particularly in the field of immunization against swine dysentery. The composition of the invention comprises bacteria from at least two genetically diverse strains of . The invention relates also to the composition of the invention for use as a vaccine, preferably a universal vaccine against swine dysentery caused by 1Brachyspira hyodysenteriaeBrachyspira hyodysenteriae. A composition comprising bacteria from at least two genetically diverse strains of , wherein the genetic diversity is conferred by selecting the at least two genetically diverse strains of from different clonal complexes (defined as the several groups established by grouping the MLVA types at the single-locus variant level) , and wherein at least one strain belongs to clonal complex II , and/or wherein at least one strain belongs to clonal complex V , and/or wherein at least one strain belongs to clonal complex I.2. The composition according to claim 1 , wherein the bacteria are inactivated.3. The composition according to claim 1 , wherein the bacteria are present at a concentration of between 10and 10of total bacteria/mL.4. The composition according to claim 1 , wherein the genetically diverse strains are detected in a proportion of at least 1% with respect to the total of detected strains in a region of interest.5. The composition of claim 4 , wherein the region of interest is Spain.6. The composition according to claim 1 , wherein the genetically diverse strains belong to the ancestral type (predicted using the goeBUST algorithm) from each clonal complex.7. The composition according to claim 1 , wherein the composition further comprises a strain which belongs to a third clonal complex claim 1 , and wherein the third clonal complex is selected from the group consisting of clonal complex I claim 1 , clonal complex II and clonal complex V.8. The composition according to claim 1 , wherein at least one of the strains belong to clonal ...

COMPOSITION AND METHOD FOR REDUCING ZOONOTIC INFECTIOUS DISEASES

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioacitve agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition. 1. A composition , comprising:a substrate,an effective amount of at least one bioactive antigenic agent layered over the substrate, wherein the bioactive antigenic agent is osmotically preconditioned in an osmotic preconditioner and stabilized in a stabilizer for substrate application;a cross-linking agent, wherein the cross-linking agent is sequentially incorporated with the stabilizer to polymerize the stabilizer for stabilization of the at least one bioactive antigenic agent under conditions facilitating anhydrobiosis2. The composition of claim 1 , wherein the composition comprises a coating or shell on the exterior surface of the composition.3. The composition of claim 1 , wherein the substrate has a mean diameter of from about 0.5 cm to about 2 cm.4. The composition of claim 1 , wherein the osmotic preconditioner comprises a sugar solution of a saline solvent base.5. The composition of claim 1 , wherein the stabilizer comprising a hydrocolloid polymer.6. The composition of claim 5 , wherein the hydrocolloid polymer comprising sodium alginate.7. The composition of claim 1 , wherein the cross-linking agent is a calcium salt selected from a group consisting of calcium lactate claim 1 , calcium butyrate claim 1 , calcium chloride claim 1 , calcium sulfate claim 1 , calcium carbonate claim 1 , calcium acetate claim 1 , and calcium ascorbate.8. The composition of claim 1 , wherein the substrate is an animal bait for enticing consumption.9. The composition ...

STRINGS OF EPITOPES USEFUL IN DIAGNOSING AND ELICITING IMMUNE RESPONSES TO SEXUALLY TRANSMITTED INFECTIONS

The invention provides methods and compositions for detecting and diagnosing sexually transmitted infections using a string of epitopes (SOE) specific for detection of causative microorganisms. The antigenic epitopes may be single epitope sequences, a plurality of epitope sequences joined by repeats of glycine (-GG-) and/or lysine (-KK-) to form a series of epitopes (SOE), or nucleotide sequences encoding one or more SOEs and host cells harboring said SOE nucleotide sequences. SOEs specific for highly immunogenic regions of proteins from and species are provided. SOEs to detect the presence of species comprise regions from -sptciric aldolase, GAPDH, a-enolase and a-actinin proteins. Pharmaceutical compositions comprising SOEs can also be used as vaccines or to elicit an immune response to specific microorganisms. 1Trichomonas vaginalis. A method for detecting the presence of one or more microorganisms in a biological sample of a subject , comprising the steps of:combining said biological sample with a polypeptide including a series of epitopes (SOE) which includes at least a plurality of SEQ ID NO: 2, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO:79-102, SEQ ID NO: 107-119, SEQ ID NO:128-133, and SEQ ID NO:137, said epitopes being arranged as a linear array with each of said epitopes being connected by an amino acid linker, wherein said combining is performed under conditions whereby antigen-antibody complexes are permitted to form; and{'i': 'Trichomonas vaginalis', 'detecting formation of at least one antigen-antibody complex as an indication of a presence of at least one microorganism of said one or more microorganisms in said biological sample.'}24-. (canceled)5Trichomonas vaginalisT. vaginalis. The method of claim 1 , wherein said microrganisms ...

Ileum-targeting, mucoadhesive thiolated hpmcp vaccine protein delivery agent

The present disclosure relates to a thiolated hydroxypropyl methylcellulose phthalate (T-HPMCP) drug delivery vehicle which is pH responsive and is loaded with either a protein drug or an antigen, to T-HPMCP microparticles, and to a production method for an ileum-specific, pH responsive, T-HPMCP drug delivery vehicle, the method including a step of loading a protein drug or an antigen onto the T-HPMCP microparticles. The T-HPMCP microparticles of the present disclosure are soluble in chlorinated methane because of the introduction of the thiol group, while a T-HPMCP drug delivery vehicle produced from the particles can efficiently effect in vivo delivery of the protein drug or antigen which is loaded thereon, since said vehicle is pH responsive such that the in vivo residence time is extended and the vehicle can act specifically on the ileum.

OspA Fusion Protein for Vaccination against Lyme Disease

Provided herein are monocot seed compositions and methods of making a monocot seed product expressing high levels of recombinant Osp fusion protein. In some embodiments, a rice seed composition is used in the manufacture of a Lyme disease vaccine formulation. In some embodiments, the composition comprising the Osp fusion protein is admixed with a drug or pharmacologically active agent, such as an antibiotic. 1Borrelia. A monocot plant-expressed fusion protein comprising cholera toxin B subunit (CTB) adjuvant fused to outer surface protein A (OspA) derived from a species , or fragment thereof.2. A formulation for oral administration to an animal , comprising a CTB.OspA fusion protein having at least 90% sequence identity to the sequence identified by SEQ ID NO: 2.3. A chimeric gene for expression of a CTB.OspA fusion protein , comprising:(i) a promoter that is active in monocot plant cells; and(ii) operably linked to the promoter, a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 1, encoding an amino acid sequence expressing a fusion protein comprising cholera toxin B subunit (CTB) adjuvant fused to an outer surface protein A (OspA) protein or fragment thereof.4. The amino acid sequence (SEQ ID NO: 2) encoded by the nucleic acid sequence of .5. (canceled)6. A transgenic monocot plant expressing a CTB.OspA fusion protein having at least 90% sequence identity to the sequence identified by SEQ ID NO: 2.7. A rice seed product comprising the fusion protein expressed by the chimeric gene of .810-: (canceled)11Borrelia. A method of immunizing an animal against infection with a species pathogen claim 3 , comprising the step of administering the CTB.OspA fusion protein to said animal.12Borrelia. The method of claim 11 , wherein the formulation is administered orally in an amount effective to induce the production of specific antibodies to the OspA claim 11 , wherein said antibodies are effective to ameliorate or clear infection by a species pathogen ...

IMMUNOGENIC COMPOSITION OF KILLED LEPTOSPIRA BACTERIA

The present invention pertains to a composition containing an immunogenic cell preparation of killed bacteria in a citric acid solution. It also pertains to a vaccine to protect an animal against an infection with bacteria, wherein the vaccine comprises this composition, and to the use of citric acid to stabilise an immunogenic preparation of killed bacteria in a liquid carrier, by dissolving the citric acid in the carrier. 110-. (canceled)11Leptospira. The composition containing an immunogenic cell preparation of killed bacteria in a citric acid solution.12. The composition of claim 11 , wherein the solution comprises 20 mmols of citric acid per litre.13. The composition of claim 12 , wherein the solution is buffered at a pH between 5 and 6.14. The composition of claim 11 , wherein the solution is buffered at a pH between 5 and 6.15LeptospiraLeptospiraLeptospiraLeptospiraLeptospira. The composition of claim 12 , wherein the bacteria are chosen from interrogans serogroup Canicola serovar Portland-Vere claim 12 , interrogans serogroup Australis serovar Bratislava claim 12 , interrogans serogroup Icterohaemorrhagiae serovar Copenhageni and kirschneri serogroup Grippotyphosa serovar Dadas.16LeptospiraLeptospiraLeptospiraLeptospiraLeptospira. The composition of claim 11 , wherein the bacteria are chosen from interrogans serogroup Canicola serovar Portland-Vere claim 11 , interrogans serogroup Australis serovar Bratislava claim 11 , interrogans serogroup Icterohaemorrhagiae serovar Copenhageni and kirschneri serogroup Grippotyphosa serovar Dadas.17LeptospiraLeptosira interrogans. The composition of claim 16 , wherein the bacteria are serogroup Australis serovar Bratislava.18LeptospiraLeptosira interrogans. The composition of composition of claim 15 , wherein the bacteria are serogroup Australis serovar Bratislava.19Leptospira. A vaccine to protect an animal against an infection with bacteria comprising the composition of .20Leptospira. A vaccine to protect an animal ...

Surface display of antigens on Gram-negative outer membrane vesicles

The present invention relates to vaccine compositions based on Gram-negative outer membrane vesicles displaying antigens of pathogens expressed as part of a fusion protein comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria, and use of such compositions in vaccination. The invention further relates to the fusion lipoproteins comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria and antigens of pathogens fused thereto, DNA constructs and bacterial host cells for expressing these fusion lipoproteins and to methods for producing outer membrane vesicles displaying the fusion lipoproteins. 115.-. (canceled)16. An OMV comprising a fusion lipoprotein , wherein the fusion lipoprotein comprises an N-terminal and a C-terminal fusion partner , wherein: i) a lipidated N-terminal cysteine;', 'ii) a tether of a surface exposed lipoprotein of a Gram-negative bacterium; and, optionally,', 'iii) a stretch of at least 5 contiguous amino acids that are located C-terminally of the tether of a surface exposed lipoprotein of a Gram-negative bacterium;, '(a) the N-terminal fusion partner comprises in N- to C-terminal orderwherein the N-terminal fusion partner causes presentation of the fusion lipoprotein on the extracellular outer membrane surface of a Gram-negative bacterium upon expression therein; and,(b) the C-terminal fusion partner comprises at least one epitope of an antigen associated with an infectious disease and/or a tumour,wherein the C-terminal fusion partner does not comprise an amino acid sequence of at least 10 contiguous amino acids from the surface exposed lipoprotein from which the sequence of the N-terminal fusion partner originates; andwherein the amino acid sequence of the fusion lipoprotein does not occur in nature.17. The OMV according to claim 16 , wherein the tether of the fusion lipoprotein is located adjacent to the lipidated N-terminal cysteine.18. The OMV according to claim 16 , wherein the ...

COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI

Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against , including administering to the subject an effective amount of the immunogenic composition 1. An immunogenic composition , comprisinga peptide, wherein consecutive amino acids of the peptide comprise consecutive amino acids of SEQ ID NO:1 and the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-193 of SEQ ID NO:1, 187-194 of SEQ ID NO:1, 188-195 of SEQ ID NO:1, 189-196 of SEQ ID NO:1, and any combination of two or more of the foregoing, andone or more adjuvants.2. The immunogenic composition of claim 1 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-218 of SEQ ID NO:1 claim 1 , 187-218 of SEQ ID NO:1 claim 1 , 188-218 of SEQ ID NO:1 claim 1 , 189-218 of SEQ ID NO:1 claim 1 , and any combination of two or more of the foregoing.3. The immunogenic composition of claim 1 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 1-193 of SEQ ID NO:1 claim 1 , 1-194 of SEQ ID NO:1 claim 1 , 1-195 of SEQ ID NO:1 claim 1 , 1-196 of SEQ ID NO:1 claim 1 , and any combination of two or more of the foregoing.4. The immunogenic composition of claim 1 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-222 of SEQ ID NO:1 claim 1 , 187-222 of SEQ ID NO:1 claim 1 , 188-222 of SEQ ID NO:1 claim 1 , 189-222 of SEQ ID NO:1 claim 1 , and any combination of two or more of the foregoing.5. The immunogenic composition of claim 1 , wherein the peptide comprises amino acids 1-218 of SEQ ID NO:1.6. The immunogenic composition of claim 1 , ...

LYME DISEASE VACCINES

The present invention relates to Lyme disease vaccines, in particular to vaccines including one or more isolated polypeptides of ss, or 1. A vaccine composition comprising:{'i': 'Borrelia burgdorferi', 'at least one polypeptide of ss chosen from SEQ ID NOs: 10, 13, 2, 8, 9, 19, 25, 29, 33, 35, 43, 45 and 85.'}2Borrelia burgdorferi. The vaccine composition as claimed in claim 1 , wherein the at least one polypeptide of ss is chosen from SEQ ID NO: 10.3Borrelia burgdorferiBorrelia afzeliiBorrelia garinii. The vaccine composition as claimed in claim 1 , comprising claim 1 , in addition to the at least one polypeptide of claim 1 , at least one polypeptide of ss claim 1 , or chosen from SEQ ID NOs: 1 claim 1 , 3 to 7 claim 1 , 11 claim 1 , 12 claim 1 , 14 to 18 claim 1 , 20 to 24 claim 1 , 26 to 28 claim 1 , 30 to 32 claim 1 , 34 claim 1 , 36 to 42 claim 1 , 44 claim 1 , 46 to 84 and 86 to 92.4Borrelia burgdorferiBorrelia afzeliiBorrelia garinii. The composition as claimed in claim 1 , comprising claim 1 , in addition to the at least one polypeptide of claim 1 , at least one other polypeptide of ss claim 1 , or chosen from the groups (c1) claim 1 , (c2) and (c3) claim 1 ,said group (c1) comprising SEQ ID NOs: 19 to 28,said group (c2) comprising SEQ ID NOs: 29 to 46 and 73 to 86,said group (c3) comprising SEQ ID NOs: 47 to 72 and 87 to 92,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'claim-text': is SEQ ID NO: 19 or 25, said at least one other polypeptide is included in the group (c2) or (c3), or', 'is SEQ ID NO: 29, 33, 35, 43, 45 or 85, said at least one other polypeptide is included in the group (c1) or (c3), or', 'is SEQ ID NO: 2, 8 or 9, said at least one other polypeptide is included in the group (c3), or', 'is SEQ ID NO: 10 or 13, said at least one other polypeptide is included in any of the groups (c1), (c2) and (c3)., 'on the condition that, if said at least one polypeptide of 5. The composition as claimed in claim 1 , further comprising a pharmaceutically ...

Immunogenic composition of killed leptospira bacteria

The present invention pertains to a composition containing an immunogenic cell preparation of killed Leptospira bacteria in an ethylenediaminetetraacetic acid solution. The invention also pertains to a vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises this composition. Also, the invention pertains to the use of ethylenediaminetetraacetic acid to stabilise an immunogenic preparation of killed Leptospira bacteria in a liquid carrier, by dissolving the ethylenediaminetetraacetic acid in the carrier.

MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a infection and a method of immunizing a subject. 117-. (canceled)18. A method for producing a polypeptide comprising a mutant fragment of an outer surface protein A (OspA) , characterized by the following steps:a) introducing a vector encoding the polypeptide into a host cell,b) growing the host cell under conditions allowing for expression of said polypeptide,c) homogenizing said host cell, andd) subjecting the host cell homogenate to purification steps.1948-. (canceled)49. The method according to claim 18 , wherein the polypeptide comprises a polypeptide selected from the group of amino acid sequences of SEQ ID NO: 185 to 208; or any functional variant of said amino acid sequences claim 18 , wherein said functional variant has a sequence identity of at least 80% to any of the sequences of SEQ ID NO: 185 to 208.50. The method according to claim 18 , wherein the polypeptide comprises a heterodimer selected from the group consisting of Lip-S1D4-S2D4 (SEQ ID NO: 185) claim 18 , Lip-S1D1-S2D1 (SEQ ID NO: 186) claim 18 , Lip-S3D4-S4D4 (SEQ ID NO: 187) claim 18 , Lip-S3D1-S4D1 (SEQ ID NO: 188) claim 18 , Lip-S5D4-S6D4 (SEQ ID NO: 189) claim 18 , Lip-S5D1-S6D1 (SEQ ID NO: 190) claim 18 , Lip-S2D4-S1D4 (SEQ ID NO: 191) claim 18 , Lip-S2D1-S1D1 (SEQ ID NO: 192) claim 18 , Lip-S4D4-S3D4 (SEQ ID NO: 193) claim 18 , Lip-S4D1-S3D1 (SEQ ID NO: 194) claim 18 , Lip-S6D4-S5D4 (SEQ ID NO: 195) claim 18 , Lip-S6D1-S5D1 (SEQ ID NO: 196) claim 18 , Lip-S1D4-S2D1 (SEQ ID NO: 197) claim 18 , Lip-S1D1-S2D4 (SEQ ID NO: 198) claim 18 , S3D4-S4D1 (SEQ ID NO: 199) claim 18 , S3D1-S4D4 (SEQ ID NO: 200) claim 18 , S5D4-S6D1 (SEQ ID NO: 201) claim ...

CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis. 118-. (canceled)19. An isolated polypeptide selected from the group consisting of:a) an isolated polypeptide comprising an amino acid sequence having at least 90 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10;b) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10; andc) an isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.2024-. (canceled)25. A composition comprising the polypeptide of and a pharmaceutically acceptable carrier.2627-. (canceled)28. An immunogenic composition comprising the composition of and an adjuvant.2934-. (canceled)35. A vaccine composition comprising the immunogenic composition of and a pharmaceutically acceptable carrier.3640-. (canceled)41. A method for inducing an immunological response in a subject claim 28 , the method comprising the step of administering the composition of to the subject in an amount effective to induce an immunological response.42. (canceled)43BorreliaBorrelia. A method for preventing or treating a infection or Lyme disease in a subject claim 35 , the method comprising the step of administering the vaccine composition of to the subject in an amount effective to prevent or treat the infection or Lyme disease.4451-. (canceled)52. The isolated polypeptide of comprising an ...

IMMUNOGENIC COMPOSITION OF KILLED LEPTOSPIRA BACTERIA

The present invention pertains to a composition containing an immunogenic cell preparation of killed bacteria in an ethylenediaminetetraacetic acid solution. The invention also pertains to a vaccine to protect an animal against an infection with bacteria, wherein the vaccine comprises this composition. Also, the invention pertains to the use of ethylenediaminetetraacetic acid to stabilise an immunogenic preparation of killed bacteria in a liquid carrier, by dissolving the ethylenediaminetetraacetic acid in the carrier. 111-. (canceled)12Leptospira. A composition containing an immunogenic cell preparation of killed bacteria in an ethylenediaminetetraacetic acid solution.13. The composition of claim 12 , wherein the solution comprises 5 to 50 mmols of ethylenediaminetetraacetic acid per litre.14. The composition of claim 13 , wherein the solution comprises 20 mmols of ethylenediaminetetraacetic acid per litre.15. The composition of claim 14 , wherein the solution contains dibasic sodium phosphate.16. The composition of claim 13 , wherein the solution contains dibasic sodium phosphate.17. The composition of claim 12 , wherein the solution contains dibasic sodium phosphate.18LeptospiraLeptospira interrogansLeptospira interrogansLeptospira kirschneri. The composition of claim 17 , wherein the bacteria are selected from the group consisting of serogroup Canicola serovar Portland-Vere claim 17 , serogroup Icterohaemorrhagiae serovar Copenhageni and serogroup Grippotyphosa serovar Dadas.19LeptospiraLeptospira interrogansLeptospira interrogansLeptospira kirschneri. The composition of claim 12 , wherein the bacteria are selected from the group consisting of serogroup Canicola serovar Portland-Vere claim 12 , serogroup Icterohaemorrhagiae serovar Copenhageni and serogroup Grippotyphosa serovar Dadas.20LeptospiraLeptospira interrogans. The composition of claim 19 , wherein the bacteria are serogroup Canicola serovar Portland-Ver.21. A vaccine to protect an animal against an ...

LIQUID STABLE VIRUS VACCINES

The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines. 1. A liquid stable vaccine that comprises a live attenuated canine or feline virus , 10-30% (w/v) sugar additive , and an amino acid; wherein the liquid stable vaccine has a pH of 6.0 to 8.0; and wherein the amino acid is selected from the group consisting of arginine and methionine; wherein when the amino acid is arginine , its final concentration in the liquid stable vaccine is 0.15 to 0.6 M; andwherein when the amino acid is methionine, its final concentration in the liquid stable vaccine is 0.025 to 0.3 M.2. The liquid stable vaccine of claim 1 , wherein the live attenuated canine virus is selected from the group consisting of canine distemper virus claim 1 , canine adenovirus type 2 claim 1 , canine parvovirus claim 1 , and canine parainfluenza virus.3. The liquid stable vaccine of wherein the canine parvovirus (CPV) is selected from the group consisting of CPV-2 claim 2 , CPV-2a claim 2 , CPV-2b claim 2 , CPV-2c claim 2 , and a recombinant CPV comprising a heterogenous CPV-2c/CPV-2 genome.4. The liquid stable vaccine of . that further comprises a component selected from the group consisting of 0.4 to 1.6% (w/v) gelatin; 0.5-2.0% (w/v) of a proteolytic hydrolysate of whole casein; 0.25 to 1.0% (v/v) ethanol; 50 to 200 μM EDTA; a buffer; and any combination thereof.58-. (canceled)9. The liquid stable vaccine of wherein the buffer comprises 2.5 to 50 mM Tris or 2.5 to 50 mM Tris and 2.5 to 50 mM histidine.10. (canceled)11. The liquid stable vaccine of claim 1 , wherein the sugar additive is selected from the group consisting of sucrose claim 1 , sorbitol claim 1 , and a combination of sugar and sorbitol.12. The liquid stable vaccine of claim 11 , wherein the live attenuated canine virus is ...

VACCINATIONS AGAINST LYME DISEASE

The presently disclosed subject matter relates to vaccinations against Lyme disease, in particular vaccinations including one or more isolated polypeptides of 1. A vaccine composition , comprising:{'i': 'Borrelia burgdorferi', 'at least one polypeptide of ss chosen from SEQ ID NOs: 103 to 125.'}2Borrelia burgdorferi. The vaccine composition according to claim 1 , further comprising at least two different polypeptides of ss chosen from SEQ ID NOs: 103 to 125.3. The vaccine composition according to claim 1 , wherein the at least one polypeptide is the polypeptide of sequence SEQ ID NO: 120 or SEQ ID NO: 124.4. The vaccine composition according to claim 2 , wherein the at least two different polypeptides are the polypeptides of sequence SEQ ID NO: 120 and SEQ ID NO: 124.5. The vaccine composition according to claim 1 , wherein the at least one polypeptide is chosen from the sequences SEQ ID NOs: 103 claim 1 , 107 claim 1 , 118 claim 1 , 120 and 124.6Borrelia burgdorferiBorrelia afzeliiBorrelia garinii. The vaccine composition according to claim 1 , further comprising at least one polypeptide of ss claim 1 , or chosen from SEQ ID NOs: 1 to 92.7Borrelia burgdorferi. The vaccine composition according to claim 1 , further comprising at least one polypeptide of ss chosen from SEQ ID NOs: 10 claim 1 , 13 claim 1 , 2 claim 1 , 8 claim 1 , 9 claim 1 , 19 claim 1 , 25 claim 1 , 29 claim 1 , 33 claim 1 , 35 claim 1 , 43 claim 1 , 45 and 85.8. The composition according to claim 1 , further comprising a pharmaceutically acceptable carrier.9. The vaccine composition according to claim 1 , further comprising an adjuvant.10. The vaccine composition according to claim 1 , further comprising at least one other active ingredient.11. The vaccine composition according to claim 1 , for use as a medicament.12. The vaccine composition according to claim 1 , for use in the prevention of Lyme disease.13Borrelia burgdorferiBorrelia afzeliiBorrelia garinii. The vaccine composition according to ...

MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a infection and a method of immunizing a subject. 148.-. (canceled)49Borrelia. A polypeptide comprising a mutant fragment of a outer surface protein A (OspA) , wherein said mutant OspA fragment comprises SEQ ID NO: 216 , or a variant thereof , wherein said variant has at least 95% sequence identity to a wild-type serotype 1 OspA fragment defined by amino acid residues 126-273 of SEQ ID NO: 20 , and wherein said variant differs from said wild-type serotype 1 OspA fragment at least by the addition of at least one disulfide bond.50. The polypeptide according to claim 49 , wherein said polypeptide comprises a heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO: 186) claim 49 , Lip-S2D1-S1D1 (SEQ ID NO: 192) claim 49 , Lip-S1D1-S2D4 (SEQ ID NO: 198) claim 49 , and Lip-S2D4-S1D1 (SEQ ID NO: 203).51. The polypeptide according to claim 49 , wherein said polypeptide consists of a heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO: 186) claim 49 , Lip-S2D1-S1D1 (SEQ ID NO: 192) claim 49 , Lip-S1D1-S2D4 (SEQ ID NO: 198) claim 49 , and Lip-S2D4-S1D1 (SEQ ID NO: 203).52. A pharmaceutical composition comprising the polypeptide according to .53. The pharmaceutical composition of claim 52 , further comprising a pharmaceutically acceptable carrier or excipient.54. The pharmaceutical composition according to claim 53 , wherein said excipient is L-methionine and/or aluminium hydroxide.55. A pharmaceutical composition comprising Lip-S1D1-S2D1 (SEQ ID NO: 186) and Lip-S5D1-S6D1 (SEQ ID NO: 190).56. The pharmaceutical composition of claim 55 , further comprising a pharmaceutically acceptable ...

STAGE SPECIFIC DIAGNOSTIC ANTIGENS, ASSAY AND VACCINE FOR LYME DISEASE

Stage-specific antigens for diagnosing, treating and/or preventing Lyme disease are provided. The antigens include chimeric antigen constructs and mutant recombinant proteins comprising OspC and OspE epitopes, respectively. The antigens are used in multiprotein assays that differentiate early, middle and late stage infection, and/or in vaccine preparations. 1. A polypeptide comprisingSEQ ID NO: 2 (RM9A61) or a variant thereof having at least 90% amino acid sequence identity or similarity to SEQ ID NO: 2; orSEQ ID NO: 4 (EurAs9v2) or a variant thereof having at least 90% amino acid sequence identity or similarity to SEQ ID NO: 4; ora recombinant mutant OspE protein that does not bind factor H, with a caveat that if said recombinant mutant OspE protein that does not bind factor H is a BBL-39 polypeptide, then the polypeptide does not have an amino acid sequence that is identical to SEQ ID NOS: 11-26.2. The polypeptide of claim 1 , wherein said recombinant mutant OspE protein that does not bind factor H is SEQ ID NO: 29 (BBN38-13) claim 1 , SEQ ID NO: 31 (BBN38-37) or a variant thereof having at least 90% amino acid sequence identity or similarity.3Borrelia. A method of detecting infection in a subject claim 1 , comprisingdetecting one or both of OspC antibodies and OspE antibodies in a biological sample from said subject; and, if one or both of said OspC antibodies or OspE antibodies are detected, then{'i': 'Borrelia.', 'concluding that said subject is infected with'}4. The method of claim 3 , wherein claim 3 , further comprising{'i': Borrelia,', 'Borrelia, 'if said subject is infected with determining whether the infection is early, middle or late stage by quantitating relative amounts of said OspC antibodies and said OspE antibodies in said sample.'}5. The method of claim 4 , further comprising{'i': 'Borrelia', 'if a quantity of OspC antibodies is greater than a quantity of OspE antibodies, then concluding that the infection is an early stage infection; and'}{'i': ' ...

Live Attenuated Heterologous Vaccine for Leptospira

The present invention provides compositions or vaccines that contain a recombinant or an attenuated that elicit an immune response in animals against infection, including compositions comprising said recombinant or attenuated , methods of vaccination against , and kits for use with such methods and compositions. 1Leptospira interrogansLeptospira interrogans. A composition or vaccine comprising a recombinant or an attenuated , wherein the comprises a mutated non-functional fliM gene.2. The composition or vaccine of claim 1 , wherein the mutated fliM gene encodes a mutated fliM protein claim 1 , and wherein the C-terminal region of the fliM protein is deleted.3. The composition or vaccine of or claim 1 , wherein the fliM gene is deleted.4. The composition or vaccine of any one of - claim 1 , wherein the fliM gene encodes an fliM protein having at least 90% sequence identity to SEQ ID NO:17 claim 1 , 18 claim 1 , 19 or 20.5. The composition or vaccine of any one of - claim 1 , wherein the fliM gene has at least 90% sequence identity to SEQ ID NO: 13 claim 1 , 14 claim 1 , 15 claim 1 , or 16.6Leptospira interrogans. The composition or vaccine of any one of - claim 1 , wherein the attenuated is deposited under the CNCM deposit Nos. CNCM I-5132 and CNCM I-5133 claim 1 , or is a progeny or descendant of CNCM I-5132 and CNCM I-5133 claim 1 , wherein the progeny or descendant comprises a mutated fliM gene encoding an fliM protein having at least 90% sequence identity to SEQ ID NO: 17 claim 1 , 18 claim 1 , 19 or 20.7Leptospira interrogans. The composition or vaccine of any one of - claim 1 , wherein the attenuated is deposited under the CNCM deposit Nos. CNCM I-5132 and CNCM I-5133 claim 1 , or is a progeny or descendant of CNCM I-5132 and CNCM I-5133 claim 1 , wherein the progeny or descendant comprises a mutated fliM gene having at least 90% sequence identity to SEQ ID NO: 13 claim 1 , 14 claim 1 , 15 claim 1 , or 16.8. The composition or vaccine of any one of - claim 1 , ...

COMPOSITION AND METHODS OF MAKING AND USING LEPTOSPIRAL LPS

The disclosure provides a method to isolate and use, e.g., in a vaccine, high molecular weight lipopolysaccharide, e.g., from 1. A method to isolate lipopolysaccharide , comprising:a) providing a mixture of an isolated culture of bacteria having lipopolysaccharide subjected to one or more freeze-thaw cycles;b) heating and/or sonicating the mixture;c) treating the heated and/or sonicated mixture with one or more nucleases;d) treating the nuclease treated mixture with one or more proteases;e) combining the protease treated mixture with a water-phenol mixture;f) isolating an aqueous layer from the water-phenol treated mixture;g) dialyzing the aqueous layer;h) subjecting the dialyzed aqueous layer to centrifugation so as to provide a pellet having lipopolysaccharide; andi) isolating and resuspending the pellet.2. The method of wherein the resuspended pellet is treated with an acid in an amount that removes lipid A from the lipopolysaccharide.3. The method of wherein bacteria is a spirochaete bacteria.4Leptospira.. The method of wherein the bacteria comprises5LeptospiraLeptospira interrogansLeptospira. The method of wherein the comprises serovars Lai or Copenhageni claim 4 , or other serovars.6. The method of further comprising treating the resuspended pellet with galactose oxidase and/or sodium periodate.7. A lipopolysaccharide containing product prepared by the method of .8. The lipopolysaccharide product of having the profile in .9. The lipopolysaccharide product of further comprising a covalently linked carrier.10. The product of wherein the carrier comprises CRM197.11. The product of wherein the carrier comprises exotoxin A.12Leptospira. A composition comprising a carrier conjugated to high molecular weight lipopolysaccharide optionally having reduced lipid A.13. (canceled)14. The composition of wherein the carrier comprises CRM197.15. The composition of wherein the carrier comprises exotoxin A.16. The composition of which is a vaccine.17. A method to vaccinate a ...

POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN

Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for Lyme disease (e.g. in canines and humans) are provided. The chimeric proteins comprise epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types and/or OspE types. The OspC types may be associated with mammalian infections. 15-. (canceled) The invention generally relates to a vaccine and diagnostic for Lyme disease. In particular, the invention provides a chimeric polyvalent recombinant protein comprising immunodominant epitopes of loop 5 and/or alpha helix 5 regions/domains of outer surface protein C (OspC) types associated with mammalian infections.Lyme disease is the most common arthropod-borne disease in North America and Europe. It is caused by the spirochetes and . Transmission to mammals occurs through the bite of infected ticks [Burgdorfer et al, 1982, Benach et al., 1983]. Considerable morbidity is associated with Lyme disease and there are areas in the United States and Europe where up to 3% of the population is infected annually [Fahrer et al., 1991]. Infection results in a multi-systemic inflammatory disease with early stage symptoms that may include erythema migrans, low-grade fever, arthralgia, myalgia, and headache [Steere et al., 1977a]. Late stage clinical manifestations can be severe and may include in part, arthritis [Steere et al., 1977a; Eiffert et al., 1998; Steere et al., 2004], carditis [Asch et al., 1994; Nagi et al., 1996, Barthold et al., 1991] and neurological complications [Nachman and Pontrelli, 2003; Coyle and Schutzer 2002]. Lyme disease has significant socio-economic costs, manifested by reductions in outdoor recreational and social activities due to concerns about tick exposure.Pharmacoeconomic studies indicate that a clear need exists for a Lyme disease vaccine, particularly in populations where the annual disease risk exceeds 1% [Meltzer et al., 1999; Shadick et al., 2001]. However, at the present time a ...

DNA ANTIBODY CONSTRUCTS FOR USE AGAINST LYME DISEASE

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating lyme disease in a subject using said composition and method of generation. 1. A nucleic acid molecule encoding one or more synthetic antibodies , wherein the nucleic acid molecule comprises at least one selected from the group consisting ofa) a nucleotide sequence encoding an anti-OspA synthetic antibody, andb) a nucleotide sequence encoding a fragment of an anti-OspA synthetic antibody.2. The nucleic acid molecule of claim 1 , further comprising a nucleotide sequence encoding a cleavage domain.3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes at least one amino acid sequence selected from the group consisting ofa) an amino acid sequence having at least about 95% identity over an entire length of the amino acid sequence to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27;b) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27; andc) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.4. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule ...

Leptospira With Increased Antigenic Mass

The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.

CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis. 1. An isolated nucleic acid molecule selected from the group consisting of:(a) a nucleic acid molecule comprising a nucleotide sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity with a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9; or SEQ ID NO: 11;(b) a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the sequence set forth in 5 SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9; or SEQ ID NO: 11;(c) a nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of the sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5; SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11;(d) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity with a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12;(e) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12, the polypeptide having a ...

Methods and compositions of protein antigens for the diagnosis and treatment of leptospirosis

Novel immunodominant antigenic proteins and peptides associated with associated with leptospirosis were identified using a proteome array based on expression of ORFs from a Leptospira genome. Compositions, methods, and uses of such antigenic proteins and peptides in the diagnosis and staging of leptospirosis infection and in compositions, methods, and uses of such antigenic is proteins and peptides in prophylactic and therapeutic vaccines are disclosed.

CANINE LYME DISEASE VACCINE

The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.

Method of treating central nervous system disorders with Borrelia burgdorferi antigen

The present invention relates to a treatment for mammalian subjects suffering from a central nervous system (CNS) disorder by administering a composition comprising an antigen at a sub-vaccine level effective to alleviate symptoms of the CNS disorder. 1Borrelia burgdorferi. A method of treating a mammalian subject suffering from a central nervous system (CNS) disorders comprising administering a composition comprising an antigen at a sub-vaccine level effective to alleviate symptoms of the CNS disorder.2. The method of claim 1 , wherein the CNS disorder is Parkinson's Disease and amyotrophic lateral sclerosis (ALS).3Borrelia burgdorferi.. The method of claim 1 , wherein the antigen is an outer surface lipoprotein of4. The method of claim 3 , wherein the outer surface lipoprotein is OspA.51Borrelia burgdorferi. The method of claim claim 3 , wherein lysed is administered as the antigen.6Borrelia burgdorferi. The method of claim 1 , wherein said composition comprises from about 1×10g to about 2×10g of outer surface lipoprotein per dose.6. The method of wherein said composition comprises about 1×10g of the outer surface lipoprotein per dose.7. The method of claim 1 , wherein the composition is administered to the subject multiple times daily.8. The method of where the composition is administered to the patient by method selected from the group consisting of sublingual claim 1 , subcutaneous claim 1 , intravenous claim 1 , intramuscular and intrathecal administration.9. The method of claim 8 , wherein the composition is administered to the subject by sublingual administration.10Borrelia burgdorferi. A composition for treatment of the symptoms of a central nervous system (CNS) disorder comprising (a) a antigen at a sub-vaccine level effective to alleviate symptoms of the CNS disorder and (b) a pharmaceutically-acceptable carrier claim 8 , diluent or adjuvant.11Borrelia burgdorferi. The composition of claim 10 , wherein the antigen is an outer surface lipoprotein.12. The ...

MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO

The present invention relates to compositions and methods for the prevention and treatment of infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a infection and a method of immunizing a subject. 1Borrelia. A polypeptide comprising a hybrid C-terminal OspA (outer surface protein A of ) fragment , wherein the hybrid C-terminal OspA fragment consists , from the N- to C-terminal direction , of{'i': Borrelia', 'B. garinii, 'i) a first OspA portion consisting of amino acids 125-176 or amino acids 126-175 of OspA from a strain that is not the corresponding fragment of , strain PBr, with SEQ ID NO: 8, and'}{'i': 'B. garinii', 'ii) a second OspA portion consisting of amino acids 176-274 or most preferably amino acids 177-274 of OspA from , strain PBr (SEQ ID NO: 8), wherein the second OspA fragment is mutant and cystine-stabilized in that it differs from the corresponding wild-type sequence at least by the substitution of the wild-type amino acid at position 182 of SEQ ID NO: 8 by a cysteine and by the substitution of the wild-type amino acid at position 269 of SEQ ID NO: 8 by a cysteine and wherein a disulfide bond between the cysteine at position 182 and the cysteine at position 269 of said second OspA fragment is present; and'}{'i': 'B. burgdorferi', 'wherein the numbering of the amino acids and of the cysteine substitutions is according to the numbering of corresponding amino acids of the full length OspA of s.s., strain B31 (SEQ ID NO: 5).'}2B. valaisianaBorrelia garinii. The polypeptide according to claim 1 , wherein the hybrid C-terminal OspA fragment consists of amino ...

Methods Of Vaccine Administration

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein. 120-. (canceled)21. A method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of vaccine , wherein the vaccine comprises modified live or attenuated Canine Distemper (CD) Virus , wherein the vaccine is administered orally in a first dose , orally in a second dose , and orally in one or more annual doses.22. The method of wherein said vaccine further comprises one or more of Canine Adenovirus-2 (Cav-2) claim 21 , and Canine Parvovirus (CPV).23. The method of claim 22 , wherein said Adenovirus-2 (Cav-2) claim 22 , and Canine Parvovirus (CPV) are attenuated or modified live viruses.24. The method of claim 23 , wherein said vaccine further comprises Canine Parainfluenza Virus (CPI).25. The method of claim 23 , wherein said vaccine is not adjuvanted.26Bordetella bronchiseptica, Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiaeL. pomona.. The method according to claim 23 , wherein the vaccine further comprises a bacterin selected from the group consisting of claim 23 , and27Bordetella bronchiseptica, Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiaeL. pomona.. The method according to claim 21 , wherein the vaccine further comprises a bacterin selected from the group consisting of claim 21 , and28. The method of claim 23 , wherein said vaccine is not adjuvanted.29Bordetalla bronchiseptica.. The method according to claim 21 , wherein the viral antigens are CD virus claim 21 , CAV-2 claim 21 , CPI virus claim 21 , and CPV claim 21 , and the bacterium in the bacterin is30. The method according to claim 21 , wherein said vaccine is not adjuvanted.31. The method ...

Composition and method for generating immunity to borrelia burgdorferi

Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition

NOVEL RECOMBINANT OUTER MEMBRANE PROTEINS FROM BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF

The present invention relates generally to the field of diarrhoeal diseases caused by intestinal spirochaetes. Specifically, the invention relates to the prevention and/or treatment of infections with . In one aspect, the invention relates to a novel recombinant polypeptide, wherein said polypeptide may preferably be combined with one or more further recombinant polypeptides. In a further aspect, an immunogenic composition containing said recombinant polypeptide(s) is provided for use in a method for treating or preventing clinical signs caused by 1. A recombinant polypeptide comprising or consisting of a sequence that is at least 70% identical to the sequence of SEQ ID NO: 1.2. The immunogenic composition of further containing a recombinant polypeptide comprising or consisting of a sequence that is at least 90% identical to the sequence of SEQ ID NO: 3 and/or a recombinant polypeptide comprising or consisting of a sequence that is at least 90% identical to the sequence of SEQ ID NO: 5.3. The recombinant polypeptide of claim 1 , wherein said polypeptide is or said polypeptide is produced by a baculovirus expression system claim 1 , preferably in cultured insect cells.4. The recombinant polypeptide of for use as a medicament.5Brachyspira hyodysenteriaeBrachyspira hyodysenteriae. A method for the treatment or prevention of clinical signs caused by or a disease caused by comprising administering a therapeutically effective immunogenic composition comprising the polypeptide of claim 1 , to an animal in need thereof.6Brachyspira hyodysenteriaeBrachyspira hyodysenteriae. A vaccine composition for the treatment or prevention of clinical signs caused by or a disease caused by comprising the polypeptide of .7. (canceled)8. A vector comprising a polynucleotide encoding the polypeptide of .9. An isolated cell comprising a vector comprising a polynucleotide encoding at least one polypeptide selected from the group consisting claim 1 , of:{'claim-ref': {'@idref': 'CLM-00001', ' ...

D-GLYCERO-B-D-HEPTOSE 1-PHOSPHATE (HMP) CONJUGATES AND USE FOR TARGETED IMMUNE MODULATION

Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject. 2. The compound of claim 1 , wherein Y is Na.3. The compound of claim 1 , wherein:R is selected from the group consisting of:{'sub': 0-6', '1-6', '0-6', '3', '1-6', '0-6', '1-6', '0-6', '0-6', '0-6', '2-6', '0-6', '2-6, '—C(O)OH, —C(O)H, —Calkyl-C(O)—Calkyl, —Calkyl-N, —Calkyl, —Calkyl —O—Calkyl, —Calkyl-aryl, —Calkyl-O-aryl, —Calkyl-C-allyl groups, and —Calkyl-O—C-allyl,'}{'sub': 0-6', '1-6', '1-6', '0-6', '1-6', '0-6', '0-6', '2-6', '0-6', '2-6, 'wherein said —Calkyl-C(O)—Calkyl, —Calkyl, Calkyl-O—Calkoxy, -aryl, Calkyl-O-aryl, Calkyl-C-allyl groups, and Calkyl-O—C-allyl is optionally substituted with a: amino, acyloxy, alkoxy, carboxyl, carbalkoxyl, hydroxy, trifluoromethyl, cyano, nitro, acyl, or a halo group;'}or{'sub': 1-6', '3', '1-6', '1-6', '3', '1-6', '1-6', '3', '1-6', '1-6', '3', '1-6', '3', '2-6, 'R is selected from the group consisting of: —Calkyl-OPOC(O)—Calkyl, —Calkyl-OPOCalkyl, —Calkyl-OPO—C—O-alkoxy, —Calkyl-OPO-aryl, and —Calkyl-OPO—C-allyl,'}{'sub': 1-6', '3', '1-6', '1-6', '3', '1-6', '1-6', '3', '1-6', '1-6', '3', '1-6', '3', '2-6, 'wherein said —Calkyl-OPOC(O)—Calkyl, —Calkyl-OPOCalkyl, —Calkyl-OPO—C—O-alkoxy, —Calkyl-OPO-aryl, —Calkyl-OPO—C-allyl group is optionally substituted with a: amino, acyloxy, alkoxy, carboxyl, carbalkoxyl, hydroxy, trifluoromethyl, cyano, nitro, acyl, or a halo group;'}orR is selected from the group consisting of:{'sub': 1-6', '3', '1-6', '1-6', '2-6', '2-6, '—C(O)OH, —C(O)H, —C(O)—Calkyl, —N, —Calkyl, —O—Calkyl, -aryl, —O-aryl, —Callyl groups, and —O—C-allyl;'}{'sub': 1-6', '1-6', '1-6', '2-6', '2-6, 'wherein said —C(O)—Calkyl, —Calkyl, —O—Calkoxy, -aryl, —O-aryl, —Callyl groups, and —O—Callyl is optionally substituted with: amino, acyloxy, alkoxy, carboxyl, carbalkoxyl, hydroxy, trifluoromethyl ...

MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO

The present invention relates to compositions and methods for the prevention and treatment of infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a infection and a method of immunizing a subject. 149.-. (canceled)50BorreliaBorrelia. A polypeptide comprising a hybrid C-terminal fragment of an outer surface protein (OspA) , wherein said hybrid C-terminal OspA fragment consists , from the N- to C-terminal direction , of a fusion of a first and second OspA portion from two different strains , wherein said second OspA portion differs from the corresponding wild-type sequence at least by the introduction of at least one disulfide bond , and wherein said polypeptide induces an immune response protective against a infection.51B. gariniiB. garinii. The polypeptide according to claim 50 , wherein said first OspA portion is from an OspA protein from a strain different to claim 50 , strain PBr claim 50 , and said second OspA portion is from the OspA protein of claim 50 , strain PBr (SEQ ID NO: 8) claim 50 , with the introduction of at least one disulfide bond.52. The polypeptide according to claim 50 , wherein{'i': Borrelia', 'B. garinii, 'i) said first OspA portion consists of amino acids 125-176 or amino acids 126-175 of OspA from a strain that is not the corresponding fragment of , strain PBr, with SEQ ID NO: 8, and'}{'i': 'B. garinii', 'ii) said second OspA portion consists of amino acids 176-274 or amino acids 177-274 of OspA from , strain PBr (SEQ ID NO: 8), wherein the second OspA fragment differs from the corresponding wild-type sequence at least by the substitution of the ...

VACCINE COMPOSITIONS FOR USE AGAINST DIGITAL DERMATITIS IN A MAMMAL

The present invention provides new pharmaceutical and vaccine compositions comprising spp. bacterins, supplemented with antigens from spp. or other digital dermatitis causative pathological agents such as but not limited to or , for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. The present invention also identifies and as two of the etiologic agents of digital dermatitis (DD) in mammals, in particular ungulate digital dermatitis. The invention therefore also provides isolated cultures of and for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. In addition, the present invention provides methods of diagnosing DD by detecting infection with a series of specific antigens. 1TreponemaTreponema. A pharmaceutical composition comprising an immunogenically effective amount of at least a spp. bacterin , and one or more isolated antigens from spp. or other digital dermatitis causative pathological agents.2TreponemaTreponema pedis, Treponema phagedenis, Treponema medium, Treponema vincentii, Treponema refringens, Treponema calligyrum, Treponema maltophilumTreponema brennaborense.. The pharmaceutical composition according to claim 1 , wherein said composition comprises an immunogenically effective amount of at least a spp. bacterin selected from the group consisting of and/or3TreponemaTreponema pedis, Treponema phagedenisTreponema medium.. The pharmaceutical composition according to claim 1 , wherein said composition comprises an immunogenically effective amount of at least a spp. bacterin selected from the group consisting of claim 1 , and/or4TreponemaTreponema pedisTreponema phagedenis.. The pharmaceutical composition according to claim 1 , wherein said composition comprises an immunogenically effective amount of at least a spp. bacterin selected from the group consisting of claim 1 , and/or5. The pharmaceutical ...

SWINE VACCINE

The invention pertains to a vaccine comprising in combination non-replicating immunogens of , porcine parvo virus, and live attenuated PRRS virus, and a pharmaceutically acceptable carrier, for use in a method for prophylactic treatment of a swine against an infection with , porcine parvo virus, and PRRS virus, wherein the vaccine is administered in a single dose with regard to the treatment against an infection with PRRS virus. 17-. (canceled)8Erysipelothrix rhusiopathiaeLeptospira interrogansErysipelothrix rhusiopathiaeLeptospira interrogans. A method for prophylactically treating a swine against an infection with , porcine parvo virus , , and PRRS virus comprising administering a vaccine comprising a pharmaceutically acceptable carrier and a non-replicating immunogen of an , a non-replicating immunogen of a porcine parvo virus , a non-replicating immunogen of a , and a live attenuated PRRS virus;wherein the vaccine is administered in a single dose with regard to the treatment against an infection with PRRS virus.9Erysipelothrix rhusiopathiaeLeptospira interrogansErysipelothrix rhusiopathiaeLeptospira interrogans. The method of claim 8 , wherein the non-replicating immunogen of the claim 8 , the non-replicating immunogen of the porcine parvo virus claim 8 , and the non-replicating immunogen of the are inactivated pathogens of the claim 8 , the porcine parvo virus claim 8 , and the claim 8 , respectively.10Leptospira interrogans. The method of claim 8 , wherein the pathogen comprises bacteria of the serogroup Pomona.11AustralisCanicola.. The method of claim 10 , further comprising a bacterium selected from the serogroup consisting of a Tarassovi claim 10 , an claim 10 , a Grippotyphosa claim 10 , an Icterohaemorrhagiae claim 10 , and a12Australis. The method of claim 11 , wherein the bacterium of the is from a serovar Bratislava.13. The method of claim 8 , wherein the vaccine is administered parenterally.14. The method of claim 8 , wherein the vaccine is ...

Композиции, содержащие химерные молекулы ospa и способы их применения

1. Композиция для предупреждения или лечения субъекта от инфекции, вызываемой бактериями Borrelia, или болезни Лайма, содержащая комбинацию полипептидов, в которой каждый из полипептидов в этой комбинации содержит аминокислотную последовательность с по меньшей мере 90, 91, 92, 93, 94, 95, 96, 97, 98 или 99% идентичности последовательности с полипептидом, содержащим аминокислотную последовательность, описанную под SEQ ID NO: 2, SEQ ID NO: 4 или SEQ ID NO: 6, или каждый из полипептидов в этой комбинации содержит аминокислотную последовательность, описанную под SEQ ID NO: 2, 4 или 6, причем указанная композиция составлена в виде стандартной дозы от около 10 мкг до около 100 мкг и фармацевтически приемлемого носителя.2. Композиция по п. 1, отличающаяся тем, что композиция составлена в виде стандартной дозы около 10 мкг, около 20 мкг, около 30 мкг, около 40 мкг, около 50 мкг, около 60 мкг, около 70 мкг, около 80 мкг, около 90 мкг или около 100 мкг.3. Композиция по п. 1, отличающаяся тем, что композиция дополнительно содержит адъювант.4. Композиция по п. 3, отличающаяся тем, что адъювант является гидроксидом алюминия.5. Композиция по п. 1, отличающаяся тем, что комбинация полипептидов содержит равное количество каждого полипептида, содержащего аминокислотную последовательность, описанную под SEQ ID NO: 2, 4 или 6.6. Композиция по п. 1, отличающаяся тем, что данная композиция является иммуногенной композицией или вакцинной композицией.7. Композиция по п. 1, отличающаяся тем, что бактерии рода Borrelia представляют собой вид Borrelia sensu lato или Borrelia sensu stricto.8. Композиция по п. 1, отличающаяся тем, что бактерии рода Borrelia представляют собой виды Borrelia afzelii, Borrelia garinii, Borrelia bavariensis, Borrelia burgdorferi sensu stricto, Borrelia japonica, Borrelia andersonii, Borrelia bissettii, Borrelia sinica, Borrelia turdi, Borrelia tanukii, Borrelia valaisiana, Borrelia lusitaniae, Borrelia spielmanii, Borrelia miyamotoi или Borrelia lonestar.9. ...

包含嵌合的ospa分子的组合物及其使用方法

本发明涉及用于新的莱姆疫苗的嵌合OspA分子的开发。更具体地，所述嵌合OspA分子包含来自一个OspA血清型的近端部分连同来自另一个OspA血清型的远端部分，同时保留了这两个亲本多肽的抗原性质。所述嵌合OspA分子被单独或组合递送以提供针对多种疏螺旋体属基因种的保护。本发明还提供向受试者施用所述嵌合OspA分子用于预防和治疗莱姆病或疏螺旋体病的方法。

Microfluidized oil-in-water emulsions and vaccine compositions

본 발명은 항원들의 면역원성을 향상시키기 위한 백신 항원보강제로서 유용한 초미세의 수중 유적형 유화액을 제공한다. 본 발명은 상기와 같은 유화액과 본질적으로 또는 비본질적으로 배합된 항원을 함유하는 백신 조성물을 또한 제공한다. 상기 유화액 및 백신의 제조 방법이 또한 본 발명에 의해 제공된다. The present invention provides an ultrafine oil-in-water emulsified emulsion useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides a vaccine composition containing an antigen inherently or non-essentially combined with such an emulsion. Methods of making such emulsions and vaccines are also provided by the present invention.

Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

본 발명은, 미생물 및 바이러스를 그들의 면역원성을 유지하면서 불활성화하기 위한 그리고 원행생물 또는 진행생물로부터 생산되는 봉입체로부터 가용성의 분해된, 리폴딩된 또는 활성 면역성 또는 치료상 단백질을 제조 및 생산하기 위한 고압 디아비스에 관한 것이다. 본 발명은 병원균을 불활성화하는 고압 방법, 및 불활성화된 병원균을 이용하여 백신 조성물을 생산하는 방법을 포함한다. 고압적으로 불활성화된 미생물은 화학적으로 불활성화된 미생물보다 더 안전하고 더 면역성이다. 유사하게, 용해된 단백질은 더 무겁게 응집된 단백질에 비해 우수한 특성 (감소된 비특이 면역 반응을 포함) 을 갖는다. The present invention is intended to inactivate microorganisms and viruses while maintaining their immunogenicity and for producing and producing soluble, degraded, refolded or active immune or therapeutic proteins from inclusion bodies produced from protozoa or progressing organisms. It relates to high pressure diabis. The present invention includes a high-pressure method for inactivating a pathogen, and a method for producing a vaccine composition using the inactivated pathogen. High pressure inactivated microorganisms are safer and more immune than chemically inactivated microorganisms. Similarly, dissolved proteins have superior properties (including reduced non-specific immune responses) compared to heavier aggregated proteins.

Mucrofluidic oil-in-water emulsion and vaccine compositions

FIELD: medicine, pharmaceutics. SUBSTANCE: invention refers to pharmaceutics and represents a vaccine composition for inducing an immune response in animals. The composition contains an antigen and a 40% oil-in-water emulsion diluted to 2.5%, wherein the above 40% oil-in-water emulsion contains 30 vl/vl % of light hydrocarbon non-metabolic oil, 10 vl/vl % of lecithin, 0.6 vl/vl % of sorbitan monooleate, 1.4 vl/vl % of polyoxyethylene sorbitan monooleate; the oil component is dispersed in an aqueous component by emulsification, while the vaccine composition is prepared by a microfluidiser. An average drop size in the composition makes less than 0.3 mcm. EFFECT: composition possesses improved physical characteristics, enhanced immunising action, as well as high safety. 10 cl, 20 ex, 17 tbl, 11 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК A61K 39/39 A61K 39/02 A61K 39/12 A61K 9/107 (13) 2 541 809 C2 (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2009113834/15, 22.03.2004 (24) Дата начала отсчета срока действия патента: 22.03.2004 Приоритет(ы): (30) Конвенционный приоритет: (73) Патентообладатель(и): Зоетис Пи ЛЛК (US) (45) Опубликовано: 20.02.2015 Бюл. № 5 (56) Список документов, цитированных в отчете о поиске: EP 1023904 A2, 02.08.2000. EP 0315153 2 5 4 1 8 0 9 R U Адрес для переписки: 129090, Москва, ул.Б.Спасская, 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры", пат.пов. А.В.Миц, рег.N 364 (54) МИКРОФЛЮИДИЗИРОВАННЫЕ ЭМУЛЬСИИ "МАСЛО В ВОДЕ" И КОМПОЗИЦИИ ВАКЦИНЫ (57) Реферат: Изобретение относится к фармацевтике и масляный компонент диспергирован в водном представляет собой композицию вакцины для компоненте путем эмульгирования, а композиция индукции иммунного ответа у животных. вакцины получена с помощью Композиция содержит антиген и 40% эмульсию микрофлюидизатора. Средний размер капель в «масло в воде», разведенную до 2,5%, где композиции составляет ...

Liquid stable viral vaccines

FIELD: veterinary medicine. SUBSTANCE: liquid stable vaccine comprises a live attenuated canine virus, 10-30% (w/v) of saccharic adjuvant, and an amino acid, wherein the liquid stable vaccine has pH value from 6.0 to 8.0. The amino acid is selected from the group consisting of arginine and methionine; if the amino acid is arginine, then its final concentration in the liquid stable vaccine is from 0.15 to 0.6 M. If the amino acid is methionine, its final concentration in the liquid stable vaccine is from 0.025 to 0.3 M. A live attenuated canine virus is selected from the group consisting of the canine distemper virus, canine adenovirus of the 2 type, canine parvovirus and canine parainfluenza virus, or any combination thereof. EFFECT: usage of the above-mentioned stabilization principle allows to produce liquid stable composition for a live attenuated canine distemper virus, canine adenovirus of the 2 type, canine parvovirus and canine parainfluenza virus. 12 cl, 2 ex, 5 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 641 970 C2 (51) МПК A61K 39/295 (2006.01) A61K 39/175 (2006.01) A61K 39/235 (2006.01) A61K 39/145 (2006.01) A61P 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 39/295 (2006.01); A61K 39/175 (2006.01); A61K 39/235 (2006.01); A61K 39/145 (2006.01) (21)(22) Заявка: 2015109724, 16.08.2013 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): ИНТЕРВЕТ ИНТЕРНЭШНЛ Б.В. (NL) Дата регистрации: 23.01.2018 21.08.2012 US 61/691,507; 12.03.2013 US 61/777,164 (43) Дата публикации заявки: 10.10.2016 Бюл. № 28 (45) Опубликовано: 23.01.2018 Бюл. № 3 (86) Заявка PCT: C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 23.03.2015 2010015180 A1, 21.01.2010. WO 2006038115 A1, 13.04.2006. US 4337242 A1, 29.06.1982. HU L. et al. Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles // J Pharm Sci., 2011, Dec; 100(12), ...

키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법

본 발명은 새로운 라임 백신에서 사용하기 위한 키메라 OspA 분자의 개발에 관한 것이다. 더 구체적으로, 키메라 OspA 분자는 하나의 OspA 혈청형으로부터의 근위 부분을 다른 OspA 혈청형으로부터의 원위 부분과 함께 포함하면서, 모 폴리펩타이드들 둘 다의 항원 특성을 보유한다. 키메라 OspA 분자는 다양한 보렐리아 동유전자종에 대해 보호를 제공하도록 단독으로 또는 조합으로 전달된다. 본 발명은 또한 라임병 또는 보렐리아증의 예방 및 치료에서 피험자에 키메라 OspA 분자를 투여하는 방법을 제공한다.

微流化水包油乳状液和疫苗组合物

本发明提供了可用作疫苗佐剂以提高抗原免疫原性的亚微型水包油乳状液。本发明还提供了含有固有地或非固有地与这种乳状液结合的抗原的疫苗组合物。本发明还提供了制备乳状液和疫苗的方法。

KSAC CHEMICAL PROTEIN EXPRESSION AND METHOD FOR PRODUCING SOLUBLE PROTEINS USING HIGH PRESSURE

1. Композиция, включающая химерный белок, состоящий из антигенов лейшмании кинетопластидного мембранного белка 11 (КМР11), стеролметилтрансферазы (SMT), А2 и цистеин протеиназы (CP).2. Композиция по п. 1, где химерный белок, по меньшей мере, на 90% идентичен последовательности SEQ ID NO: 2.3. Композиция по п. 1, где химерный белок кодируется полинуклеотидом, идентичным, по меньшей мере, на 90% последовательности SEQ ID NO: 1.4. Композиция по п. 1, где химерный белок является фактически солюбилизированным в водном растворе или фактически подвергнутым рефолдингу.5. Композиция по п. 1, где химерный белок солюбилизирован или подвергнут рефолдингу с помощью высокого давления.6. Композиция по п. 5, где высокое давление составляет от около 1000 бар до около 5000 бар.7. Композиция по п. 6, где высокое давление применяется в течение, по меньшей мере, 20 ч.8. Композиция по п. 5, где химерный белок солюбилизирован или подвергнут рефолдингу из телец включения Е. coli.9. Композиция по п. 8, где тельца включения Е. coli получают в буфере, не содержащем или содержащем пониженный уровень мочевины.10. Композиция по п. 8, где тельца включения Е. coli получают в буфере, содержащем дитиотреитол (DTT).11. Композиция по п. 9 или 10, где тельца включения Е. coli дополнительно подвергаются высокому давлению в диапазоне от около 1000 бар до около 5000 бар.12. Композиция по п. 11, где тельца включения Е. coli обрабатываются при высоком давлении в течение от около 20 ч до около 100 ч.13. Композиция по п. 12, где тельца включения Е. coli подвергаются снижению давления со скоростью около 83 бар/ч-125 бар/ч.14. Композиция по п. 5, где высокое давление повышается поэтапным способом.15. Способ лечения или предотвращения лейшманиоза у животного, восприимчивого к инфекции лейшамании, путем индукции у животного иммунного ответа против РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК A61K 39/008 (13) 2015 111 255 A (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21 ...

Canine Lyme disease vaccine

本发明提供了一种用于犬莱姆病的疫苗以及单独或与其他保护剂组合制备和使用所述疫苗的方法。

Toreponema hyodicenteriae bacterin and its method

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Microfluidised oil-in-water emulsions and vaccine compositions

FIELD: medicine; biotechnologies. SUBSTANCE: vaccine composition contains saponin glycoside, sterol and antigen, where specified saponin glycoside and specified sterol are associated with each other to create complexes in the form of helical micelles. Specified antigen is mixed with specified helical micelles, but is not included into their composition. Vaccine contains saponin glycoside and sterol with the weight proportion of saponin to sterol - from 1:100 to 5:1. Specified saponin glycoside and specified sterol are associated with each other to create complexes in the form of helical micelles with immunopotentiating activity. Vaccine additionally contains immunologically efficient amount of antigen. Specified antigen is mixed with specified helical micelles, but is not included into their composition. Adjuvant oil-in-water composition contains Quil A and cholesterol with weight proportion of saponin and sterol from 1:100 to 5:1 in carrier acceptable for veterinary medicine. Specified Quil A and cholesterol are associated with each other to create complexes in the form of helical micelles with immunopotentiating activity, where oil used is non-metabolised oil. Besides specified helical micelles are microfluidized with carrier acceptable for veterinary science to produce submicron oil-in-water emulsion. Method of vaccine production according to clause 1, comprising the following stages: a) preparation of antigen composition in buffer; b) addition of saponin to composition from stage a); and c) addition of sterol in alcohol to composition from stage b). This invention is related to submicron oil-in-water emulsions, which are acceptable as vaccine adjuvant. Besides the present invention is related to vaccine compositions that contain antigen combined directly in composition of such vaccine or separately. EFFECT: higher immunogenicity of antigens. ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß RU (19) (11) 2 347 586 (13) C2 (51) ÌÏÊ A61K 39/39 A61P 31/00 (2006.01) (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ...

VACCINES FOR DOGS AGAINST BORDETELLA BRONCHISEPTICA

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (11) 2005 124 130 (13) A (51) ÌÏÊ A61K 31/495 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2005124130/15, 15.01.2004 (71) Çà âèòåëü(è): ÏÔÀÉÇÅÐ ÏÐÎÄÀÊÒÑ ÈÍÊ. (US) (30) Ïðèîðèòåò: 29.01.2003 US 60/443,418 (43) Äàòà ïóáëèêàöèè çà âêè: 20.01.2006 Áþë. ¹ 02 (86) Çà âêà PCT: IB 2004/000146 (15.01.2004) Àäðåñ äë ïåðåïèñêè: 129010, Ìîñêâà, óë. Á.Ñïàññêà , 25, ñòð.3, ÎÎÎ "Þðèäè÷åñêà ôèðìà Ãîðîäèññêèé è Ïàðòíåðû", ïàò.ïîâ. Ã.Á. Åãîðîâîé R U Ôîðìóëà èçîáðåòåíè 1. Âàêöèííà êîìïîçèöè , âêëþ÷àþùà êîëè÷åñòâà àíòèãåíà p68 Bordetella bronchiseptica è àäúþâàíòà, ýôôåêòèâíûå, ÷òîáû çàùèùàòü ñîáàê ïðîòèâ Bordetella bronchiseptica. 2. Âàêöèííà êîìïîçèöè ïî ï.1, â êîòîðîé âûøåóïîì íóòûé àíòèãåí p68 Bordetella bronchiseptica âêëþ÷àåò àìèíîêèñëîòíóþ ïîñëåäîâàòåëüíîñòü, ïðåäñòàâëåííóþ â SEQ ID ¹ 1, è ïîëó÷åí ðåêîìáèíàíòíî. 3. Âàêöèííà êîìïîçèöè ïî ï.1, â êîòîðîé âûøåóïîì íóòûé àäúþâàíò âêëþ÷àåò Quil A è õîëåñòåðèí. 4. Ñïîñîá çàùèòû ñîáàê ïðîòèâ Bordetella bronchiseptica, âêëþ÷àþùèé ââåäåíèå ñîáàêå âàêöèííîé êîìïîçèöèè ïî ëþáîìó èç ïï.1-3. 5. Êîìáèíèðîâàííà âàêöèíà äë èììóíèçàöèè ñîáàê ïðîòèâ ñîáà÷üèõ ïàòîãåíîâ, âêëþ÷àþùà ïðåïàðàò àòòåíóèðîâàííîãî øòàììà âèðóñà ÷óìû ñîáàê (CD), àòòåíóèðîâàííîãî øòàììà àäåíîâèðóñà ñîáàê òèïà 2 (CAV-2), àòòåíóèðîâàííîãî øòàììà âèðóñà ïàðàãðèïïà ñîáàê (CPI) è àòòåíóèðîâàííîãî øòàììà ïàðâîâèðóñà ñîáàê (CPV); èíàêòèâèðîâàííûé, ïîëó÷åííûé èç öåëüíûõ êëåòîê èëè èõ ÷àñòåé, ïðåïàðàò øòàììà êîðîíàâèðóñà ñîáàê (CCV), áåëîê p68 Bordetella bronchiseptica è àäúþâàíò. 6. Êîìáèíèðîâàííà âàêöèíà ïî ï.5, â êîòîðîé âûøåóïîì íóòûé àíòèãåí p68 Bordetella bronchiseptica âêëþ÷àåò àìèíîêèñëîòíóþ ïîñëåäîâàòåëüíîñòü, ïðåäñòàâëåííóþ â SEQ ID ¹ 1, è ïîëó÷åí ðåêîìáèíàíòíî. 7. Êîìáèíèðîâàííà âàêöèíà ïî ï.5, â êîòîðîé âûøåóïîì íóòûé àäúþâàíò âêëþ÷àåò Quil À è õîëåñòåðèí. Ñòðàíèöà: 1 RU A 2 0 0 5 1 2 4 1 3 0 A (54) ÂÀÊÖÈÍÛ ÄËß ÑÎÁÀÊ ÏÐÎÒÈ BORDETELLA BRONCHISEPTICA 2 0 ...

Emulsion vaccine produced from heated bacterin

FIELD: medicine, pharmaceutics. SUBSTANCE: invention concerns a vaccine for preventing an infection caused by at least one of Leptospira, bovine herpes virus, parainfluenza virus and bovine respiratory syncytial virus. The presented vaccine contains heated bacterin Leptospira having the lipase activity of 50% or less as compared to the pre-heating lipase activity of bacterin and maintaining the antigenic activity, and 1-3 live viruses specified in a group consisting of bovine herpes virus, parainfluenza virus and bovine respiratory syncytial virus. The above heating involves Leptospira bacterin heating to temperature 60°C to 70°C for the period of time from 5 to 10 hours. EFFECT: invention enables producing the stable vaccines maintaining the virus infectivity. 7 cl, 5 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 569 457 C2 (51) МПК A61K 39/00 (2006.01) A61K 39/02 (2006.01) A61K 39/295 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2011115400/10, 20.04.2011 (24) Дата начала отсчета срока действия патента: 30.08.2007 Приоритет(ы): (30) Конвенционный приоритет: (73) Патентообладатель(и): Зоитис Пи ЭлЭлСи (US) 2 5 6 9 4 5 7 R U (56) Список документов, цитированных в отчете о поиске: J.A.ZEIGLER et al., Immunization against leptospirosis: vaccine trials with heatkilled whole cell and outer envelope antigens, Bulletin of the Pan American Health Organization,1976, Vol.X, no.2, p.126-130. US 20040185062 A1, 23.09.2004. RU 2005124130 A, 20.01.2006. Адрес для переписки: 191036, Санкт-Петербург, а/я 24, "НЕВИНПАТ", пат.пов. А.В.Поликарпову (54) ЭМУЛЬСИОННАЯ ВАКЦИНА, ПОЛУЧЕННАЯ ИЗ ОБРАБОТАННОГО НАГРЕВАНИЕМ БАКТЕРИНА (57) Реферат: Изобретение касается вакцины для антигенную активность, и 1-3 живых вируса, предупреждения инфекции, вызванной по выбранных из группы, состоящей из герпесменьшей мере одним из Leptospira, герпес-вируса вируса коров, вируса парагриппа и коровьего коров, вируса парагриппа и коровьего ...

Dbpa antibodies and uses thereof

Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g ., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia . Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.

Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon

Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the Leptospira OMPs can be used to create, manufacture or improve vaccines. Vaccines, including but not limited to DNA vaccines, recombinant vaccines, and T-cell epitope vaccines based on the foregoing OMPs are also provided. Methods for producing such vaccines are also provided. Also provided are methods for using Leptospira OMP genes, proteins and antibodies for therapeutic treatment and serological diagnosis techniques.

Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof

Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species

Ospa chimeras and use thereof in vaccines

본 발명은 라임 질환에 대항 또는 보렐리아증 백신에 사용하기 위한 키메라 OspA 분자의 개발에 관한 것이다. 보다 구체적으로, 상기 키메라 OspA 분자는 또 다른 OspA 혈청형으로부터의 원거리 부분과 함께 하나의 OspA 혈청형으로부터 인접한 부분을 포함하고 모 폴리펩타이드 둘다의 항원성 성질을 보유한다. 상기 키메라 OspA 분자는 다양한 보렐리아 동유전자종으로부터의 보호를 제공하기 위해 단독으로 또는 조합하여 전달된다. The present invention relates to the development of chimeric OspA molecules for use in a vaccine against Lyme disease or in a borreliosis vaccine. More specifically, the chimeric OspA molecule comprises a contiguous portion from one OspA serotype with a distal portion from another OspA serotype and retains the antigenic properties of both parental polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection from various Borrelia allogenes.

Immunogenic proteins form genome-derived outer membrane of leptospira and compositions and methods based thereon

Leptospira outer membrane protein (OMP) LP1118 is provided. The OMP can be used as a tool for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP gene are further provided. The antigenic properties of the Leptospira OMP can be used to create, manufacture or improve vaccines. Vaccines, including but not limited to DNA vaccines, recombinant vaccines, and T-cell epitope vaccines based on the foregoing OMP are also provided. Methods for producing such vaccines are also provided. Also provided are methods for using Leptospira OMP genes, proteins and antibodies for therapeutic treatment and serological diagnosis techniques.

Compositions and methods for delivery of genetic material

Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.

Compositions and methods for delivery of genetic material

Methods of introducing genetic material into cells of an individual and compositions and kits for practising the same are disclosed. The methods comprise the steps of contacting cells of an individual with a genetic vaccine facilitator and administering to the cells a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed. Pharmaceutical compositions and kits for practising methods of the present invention are disclosed.

Compositions and methods for delivery of genetic material

Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional, or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against pathogens are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.

Compositions and methods for delivery of genetic material

Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV am disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.

Antigen library immunization

This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.

Synthetic vaccine agents

The present invention provides for novel immungens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic determinant includes a B-cell or CTL epitope and the 2nd antigenic determinant includes a T-helper epitope. In preferred embodiments, the antigenic determinants are derived from different molecules and species. Exemplary immunogens of the invention are constituted of a linear tresyl-activated dextran backbone to which is coupled B-cell or CTL epitopes of an antigen and to which is also coupled universal T-helper epitopes. Also disclosed are immunogenic compositions comprising the immunogens, methods of immunisation and a method for identification of suitable immunogens of the invention.

Combinatorial analysis and repair

A method for the repair of a unit, by specific diagnosis of the undesired state, and its appropriate repair, using said specific diagnosis as a means to repair in an appropriate way said unit. The diagnosis and repair processes may involve chemical, physical, or mechanical means. The units being diagnosed and repaired include live matter (e.g. human beings, animals, plants) as well as non-live matter (e.g. buildings, electronic equipment, polymer materials).

POLYVALENT VACCINES FOR DOGS AGAINST Leptospira bratislava AND OTHER PATHOGENS

FIELD: medicine. SUBSTANCE: group of inventions relates to field of veterinary medicine. Combined vaccine against dog's leptospirosis contains preparation of Leptospira cells from Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae and Leptospira pomona and a carrier. Quantity of each Leptospira strain in combined vaccine is in the range of nearly 100-3500 nephelometric units per a dose of vaccine. Combined vaccine for immunisation of dogs against dogs' pathogens additionally contains attenuated strain Snyder Hill of dogs plague virus (CD), attenuated strain Manhattan of adenovirus of dogs of 2 type (CAV-2), attenuated strain of virus NL-CPI-5 of dogs parainfluenza (CPI), attenuated strain NL-35-D of dogs' parvovirus (CPV) and carrier, where said virus CD, CAV-2, virus CPI and CPV are in the range from ot 10 2 to 10 9 TCID 50 (inflectional dose with 50% cytopathic effect in tissue culture) per a dose. Method of dog's protection against leptospirosis and other pathogens includes introduction to a dog of said above combined vaccines in therapeutically effective quantity. EFFECT: vaccines and method have high efficiency, are harmless. 15 cl, 4 dwg, 49 tbl, 6 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 400 248 (13) C2 (51) МПК A61K 39/295 (2006.01) A61P 31/04 (2006.01) A61P 31/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21), (22) Заявка: 2007112480/13, 23.09.2005 (30) Конвенционный приоритет: 06.10.2004 US 10/959,757 (73) Патентообладатель(и): Пфайзер Продактс Инк. (US) (43) Дата публикации заявки: 20.11.2008 2 4 0 0 2 4 8 (45) Опубликовано: 27.09.2010 Бюл. № 27 (56) Список документов, цитированных в отчете о поиске: WO 2004067031 А, 12.08.2004. RU 2030915 C1, 20.03.1995. US 2004081666 A1, 29.04.2004. (85) Дата перевода заявки PCT на национальную фазу: 07.05.2007 2 4 0 0 2 4 8 R U (87) Публикация PCT: WO 2006/038115 (13.04. ...

Canine vaccines against bordetella bronchiseptica

This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.

Microfluidized oil-in-water emulsions and vaccine compositions

This invention provides submicron oil-in water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.

Multivalent canine vaccines against leptospira bratislava and other pathogens

This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.

Canine combination vaccines

This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica . This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica , canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona . The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.

Microfluidized oil-in-water emulsions and vaccine compositions

This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.

Vaccine compositions comprising saponing glycoside, sterol and antigen